Creation of Innovation Centers for Advanced Interdisciplinary

Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program

Project for Developing Innovation Systems

Ministry of Education, Culture, Sports, Science and Technology（MEXT） Science and Technology Policy Bureau University-Industry Collaboration and Regional R&D Division Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program3-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-8959, Japan Tel : +81-(0)3-5253-4111 2014.03

東京大学The University of Tokyo

Creation of Innovation Centers forAdvanced Interdisciplinary Research Areas Program

INDEXCreation of Innovation Centers for Advanced Interdisciplinary Research Areas Program

2006 2007 2008

The Ministry of Education, Culture, Sports, Science and Technology (MEXT) emphasiz-

es the importance of creating continuous innovation by making the best use of its ba-

sic scientific and engineering capabilities in order to secure a sustainable competitive

advantage for Japan in the international community.

Generating new knowledge by maximizing the effects of synergy through the fusion

of different disciplines is also required in order to meet diversified social needs. Being

aware of such needs, MEXT has operated since FY 2006 a program for the “Creation

of Innovation Centers for Advanced Interdisciplinary Research Areas.”

This program is expected to create R&D centers and strengthen the capacity of re-

searchers and engineering staff shouldering next-generation needs in advanced inter-

disciplinary research areas.

The aim of this program is to overcome the so-called “valley of death” through inte-

grated industry-academia collaboration focusing on future commercialization.

Twelve centers are currently being operated in advanced interdisciplinary research ar-

eas such as nanotechnology, biotechnology, IT, and the like, as well as in fields such

as engineering, medicine, pharmacology, and physical sciences. These centers strongly

promote R&D for creating innovation with enormous social and economic impact,

such as the creation of new industries that can be expected to emerge in 10–15 years,

through not only the involvement of universities but the active participation and com-

mitment of enterprises (with a matching fund format). Products have already been

commercialized in several areas. This program can be expected to become good prac-

tices for innovation creation in Japan.

Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program

Project for Developing Innovation Systems

Project Guide 02

Locations 03

Adopted FY2006

Kyoto University Innovative Techno-Hub for Integrated Medical Bio-Imaging 04

The University of Tokyo COE for Nano Quantum Information Electronics 08

Hokkaido University 12

Tokyo Women’s Medical University 16

In-Depth Focus � 20

Adopted FY2007

Osaka University Photonics Advanced Research Center� 22

The University of Tokyo Translational Systems Biology and Medicine Initiative� 26

Tohoku University R&D Center of Excellence for Integrated Microsystems� 30

Kyushu University Innovation Center for Medical Redox Navigation� 34

Kyoto University � 38

Adopted FY2008

Yokohama City University � 44

� 48

Kobe University Innovative Bio Production Kobe (iBioK) � 52

March 2014University-Industry Collaboration and Regional R&D Division Science and Technology Policy Bureau Ministry of Education, Culture, Sports, Science and Technology

Kyoto�U�adopted�FY2007�is�here

The Matching Program for Innovations in Future Drug Discovery and Medical Care

Advanced Interdisciplinary Center for the Establishment of Regenerative Medicine

Innovation Center for Immunoregulation Technologies and Drugs

Establishment of Research Center for Clinical Proteomics of Post-Translational Modifications

Vertically Integrated Center for Technologies of Optical Routing toward Ideal Energy Savings （VICTORIES）

National Institute of Advanced Industrial Science and Technology

ProjectsCreation of Innovation Centers for Advanced Interdisciplinary Research Areas Program

2006 2007 2008

OverviewCreation of Innovation Centers for Advanced Interdisciplinary Research Areas Program

2006 2007 2008

東京大学The University of Tokyo

拠　　点

Tokyo Women’s Medical University

Advanced Interdisciplinary Center for the Establishment of Regenerative Medicine

Collaborating Organizations:Dai Nippon Printing Co., Ltd., Cell-Seed Inc., Hitachi, Ltd.

Tohoku University

R&D Center of Excellence for Integrated Microsystems

Collaborating Organizations : Ricoh Company, Ltd., Toppan Technical Design Center Co., Ltd., Mems Core Co., Ltd., Kitagawa Iron Works Co., Ltd., Sumitomo Precision Products Co., Ltd., Toyota Motor Corporation, The Nippon Signal Co., Ltd., Nidec Copal Electronics Corporation, Nihon Dempa Kogyo Co., Ltd., Pioneer Corporation, MEMSAS Inc., Toyota Central R&D Labs., INC., NIKKO Company, Japan Aviation Electronics Industry, Ltd., Furukawa Electric Co., Ltd., Denso Corporation

Hokkaido UniversityCollaborating Organizations : Shionogi & Co., Ltd., Hitachi, Ltd., Sumitomo Bakelite Co., Ltd., Nihon Medi-Physics Co., Ltd., Mitsubishi Heavy Industries, Ltd.

Kyushu University

Innovation Center for Medical Redox Navigation

Collaborating Organizations : JEOL Ltd., Shimadzu Corporation, M i t s u b i s h i T a n a b e P h a r m a Corporation, Taiho Pharmaceutical Co., Ltd., HOYA Corporation, Fuji Electric Co., Ltd., NOF Corporation, Kyushu Electric Power Co., Inc.

Kobe University

Innovative Bio Production Kobe (iBioK)

Collaborating Organizations : ASAHI KASEI CHEMICALS CORPORATION, EZAKI GLICO CO., LTD., Kaneka Corporation, Gekkeikan Sake Company, Ltd., COSMO OIL CO., LTD., DAICEL CORPORATION, TEIJIN LIMITED, Nagase & Co., Ltd., NITTO DENKO CORPORATION, NIPPON SHOKUBAI CO., LTD., NIPPON PAPER INDUSTRIES CO., LTD., Bio-energy Corporation, Fujicco Co., Ltd., Mitsui Chemicals, INC.

National Institute of Advanced Industrial Science and Technology

Vertically Integrated Center for Technologies ofOptical Routing toward Ideal Energy Savings (VICTORIES)

Collaborating Organizations : Nippon Telegraph and Telephone Corpora-tion, Fujitsu Laboratories Ltd., Furukawa Electric Co., Ltd., Trimatiz Ltd., NEC Corporation, Fujitsu Ltd., Fujikura Ltd., Alnair Labs Corporation, Sumitomo Electric Industries, Ltd., Kitanihon Electric Cable Co., Ltd.

Kyoto University

Innovative Techno-Hub for Integrated Medical Bio-Imaging

Collaborating Organizations : Canon Inc., Otsuka Pharmaceutical Co., Ltd.

Kyoto University

Innovation Center for Immunoregulation Technologies and Drugs

Collaborating Organizations : Astellas Pharma Inc.

Yokohama City University

Collaborating Organizations : Medical ProteoScope Co., Ltd., Lion Corporation, FUJIFILM Corporation, Eisai Co., Ltd., FANCL Corporation, TOSOH Corporation, Sekisui Medical Co., Ltd., Toyama Chemical Co., Ltd, CellFree Sciences Co., Ltd.

Osaka University

Photonics Advanced Research Center

Collaborating Organizations : Shimadzu Corporation, Sharp Corporation, Nitto Denko Corporation, Mitsubishi Chemical Group Science and Technology Research Center, Inc., IDEC Corporation

The University of Tokyo

COE for Nano Quantum Information Electronics

Collaborating Organizations : Sharp Corporation, NEC Corpo-ration, Hitachi, Ltd., Fujitsu Laboratories Ltd., QD Laser, Inc.

The University of Tokyo

Translational Systems Biology and Medicine Initiative

Collaborating Organizations: Forerunner Pharma Research Co., Ltd., Olympus Cor-poration, Sekisui Medical Co., Ltd., Toray Industries Inc., Mitsubishi Tanabe Pharma Corporation, Hitachi Aloka Medical, Ltd., Nikon Corporation, Kowa Company, Ltd.

Innovative Bioproduction KOBE

Implementation Scale

Implementation Period

In the 3 years before the review About 300 million yen per year

After full-scale implementation About 500–700 million yen per year

During the initial 3 years, centers that have made proposals are shortlisted.A review is conducted in the 3rd year (after 2.5 years and 3.5 years) to narrow down the list by two-thirds.Themes that proceed to actual implementation shall continue to be imple-mented over the next 7 years. A total of 21 themes were selected between 2006 and 2008. Currently, 12 of these are underway.

Universities, inter-university research institute corporations, national research institutes, and incorporated administrative agencies(Participants are obliged to come up with joint proposals with the industrial world, which is also expected to shoulder a reasonable amount of the cost.)

Participants

先端融合拠点形成

次世代を担う研究者・技術者の育成

産学協働で社会・経済的インパクトのある

イノベーションを推進する拠点を形成

要素技術（企業、大学）の

参画

他先端領域との連携

協働体制の構築

開発力（企業）

先端的なコア技術（大学）

ER1 R2

Creation of Centers for Advanced Interdisciplinary ResearchCreate centers to promote innovations that have social and economic impact

through collaboration between industry and academia.

Tie-ups in otheradvanced areas

Advanced core technologies

(universities)

Development capabilities (companies)

Inclusion ofcomponent technologies (company, universities)

ER1 R2

Construction ofcollaboration system

Development ofresearchers and engineering

staff to shoulder next-generation needs

This program aims to support the creation of innovation centers that have significant social and

economic impact, such as the generation of new industries. The program will achieve this goal by

matching academia with industries in advanced interdisciplinary research areas considered to be

especially important for innovation.

To overcome the “valley of death,” creating R&D innovation centers to conduct basic research through industry-academic collaboration

Based on collaboration between industry and academia, create a system with the seeds sown by universities as its core, in order to realize innovation in advanced interdisciplinary research areas.

rs for A

s Prog

Kyoto UniversityInnovative Techno-Hub for Integrated Medical Bio-Imaging

Fusion of Kyoto University’s integrated scientific-technological knowledge and excellent clinical research achievements with the collaborating organization’s technical strengths in product development to create the social value through the realization of innovative imaging-diagnosis techniques and modalities.

ORGANIZATION

Name Kyoto University

U R L http://ckpj.t.kyoto-u.ac.jp/?lang=en

Address Yoshida Hon-machi, Sakyo-ku, Kyoto 606-8501, Japan TEL. +81-75-753-4896 FAX. +81-75-753-9147Overall Person-in-charge Hiroshi Matsumoto (President, Kyoto University)

Researcher (Representative) Nagahisa Yoshimura (Professor, Graduate School of Medicine)/

Teruyuki Kondo (Professor, Advanced Biomedical Engineering Research Unit)

Implementation Period FY2006 – FY2015

Collaborating Organizations : Canon Inc., Otsuka Pharma-

ceutical Co., Ltd.

■ 7th Year (FY2012)

1 A clinical trial of the prototype equipment of retinal optical

imaging system (OCT/SLO) has been started for the product as-

sessment.

2 The higher functions and technologies for the integration of

ultrasound and optical imaging (US/PAT) have been established,

and the prototype equipment of photoacoustic mammography

(PAM) has been introduced.

3 The sensitivity of atomic magnetometers (AMMs) has been

improved. Compact module-type AMMs have been fabricated.

Bio-magnetic signals as well as MR signals in ultra-low magnetic

fields have been observed.

■ After Project Ends (around 2017)

1 Industrial application of the basic, collaborative and interdisci-

plinary researches should be continued at a world top-level base

institution of Kyoto University.

2 The talented researchers in interdisciplinary research areas of

medicine and engineering, who can play an active and important

part in industry and the medical institutions, should be fostered

through the clinical cooperation.

1 Through the collaboration with IIIM, OCT and SLO equipment

with new functions will be realized.

2 The development of the integrated image diagnosis system

for US will be completed, and the prototype equipment with a

new principle/multi-modality based on PAT imaging will be es-

tablished.

3 A fused imaging system to detect multiple bio-magnetic sig-

nals with ultra-sensitive AMM modules will be realized.

4 The innovative molecular probes will be developed, and the

strictly selected molecular probes will be applied to pre-clinical

trials.

Collaboration System1

2 Overall Concept

The CK project combines Kyoto University’s

integrated scientific-technological knowledge

and excellent clinical research achievements

with the Canon Inc.’s technical strengths in

product development. Since 2012, Otsuka

Pharmaceutical Co., Ltd. has participated in

the project to accelerate the development of

molecular imaging probes.

The aim of the project for ten years is the

realization of innovative imaging-diagnosis

techniques and equipment including the de-

velopment of innovative molecular imaging

probes. Ultimately the program seeks to con-

tribute to the creation of “healthy society” by

promoting cutting-edge research and devel-

opment, while fostering talented researchers

in interdisciplinary research areas of medicine

and engineering.

The university system for the intellectual prop-

erty has been reformed to accelerate the real-

ization of the invented technologies through

the academia-industry collaboration. The

base institutions for the project are the Kyoto

University Hospital including Clinical Research

Center for Medical Equipment Development

(CRCMeD) on Kyoto University’s Yoshida cam-

pus, the Int’tech Center on Katsura campus,

and Canon Inc. in Shimomaruko, Tokyo. A

world top-level base institution will be estab-

lished at Kyoto University to foster talented

researchers in interdisciplinary research areas

of medicine and engineering.

RESEARCH THEME

Development of a retinal optical imaging system (OCT/

SLO) that simultaneously achieves high definition and a

high imaging speed

Establishment of the highly advanced medical care to de-

tect complications of lifestyle-related diseases appeared in

the fundus and retinal diseases

Social Value Improvements of the Quality of Life (QOL)

of patients through the early diagnosis of fundus and reti-

nal diseases that may cause vision loss.

Economic Value Contribution to the reduction of both

medical expenses and economic losses caused by severe

vision impairment

Expected Market Scale/Expected Achievement Period

80 billion yen (global market scale)/4 years after end of

implementation period

Results to Date The potential now exists to detect initial

changes in the key ophthalmological diseases and vascu-

lar lesions in the lifestyle diseases through the research

and development of the “high-speed and wide-angle

prototype OCT” with a

5 μm horizontal reso-

lution capability and a

“High-Resolution pro-

totype AOSLO” based

on aberration error-cor-

rection technology.

Kyoto UniversityInnovative Techno-Hub for Integrated Medical Bio-Imaging

1 Development of Retinal Optical Imaging Technologies (OCT/SLO)

Development of novel technologies of ultra-sensitive

optically-pumped atomic magnetometers (AMMs) not

requiring cryogenic cooling, compact and array AMMs,

and related signal processing

Application of such technologies to ultra-low field MRI

and bio-magnetic imaging, represented by magnetoen-

cephalography and magnetocardiography

Social Value New diagnostic methodologies through

development of a multimodal bio-magnetic imaging sys-

tem with MRI

Economic Value Creation of a new market by the devel-

opment of a compact and handy multimodal bio-mag-

netic imaging system

3 Development of Magnetic Sensing/MR Imaging Technologies with AMM (AMM/MRI)

Implements for a clinical decision support system using

a comprehensive dataset consisting of multiple imaging

modalities and various kinds of clinical information

Social Value Reducing doctors’ workload and improve-

ment of the accuracy of clinical diagnosis

Economic Value The system encourages people to

utilize their own personal healthcare information to

improve the quality of medical treatment for them.

Deployment of the system as a social infrastructure

creates a big business chance, and, at the same time,

lessens the burden of medical bill on the society.

1 trillion yen (global market scale)/4 years after end of

Results to Date We have built a large database on lung

nodules, and computer inference system using the data-

Subsequently, we are currently verifying the clinical ben-

efit of the system, and also developing a computer aided

diagnosis system for OCT imaging.

5 Development of Computer Aided Diagnosis System (IIIM)

Collaborating Organizations : Canon Inc.

Development of novel ultrasound-based technologies

with excellent features such as non-invasive, real-time,

compact, and handy to acquire information on tissue

characteristics and higher-order functions

Commercialization of a new imaging technology for bi-

ological functions that integrates ultrasound and optical

imaging (US/PAT)

Social Value Improvement of diagnostic accuracy for

breast cancer of young ladies as well as seniors

Economic Value Widespread use of new modality, PAM,

even in small clinics, which greatly contribute to reduce

medical cost and improve patient benefit

Results to Date We have succeeded in developing the

ultra-high resolution technology in ultrasound (US) im-

aging through adaptive signal processing and the tissue

property imaging technology based on the measurement

of tissue viscoelasticity and 2D displacement vector. We

have just started a clinical research of photoacoustic

mammography (PAM), and

obta ined images of oxy-

gen-saturated and unsatu-

rated haemoglobins in the

blood vessels of the breast

cancer.

2 Development of Ultrasound and Photoacoustic Imaging Technologies (US/PAT)

A performance enhancement of minimally-invasive

probe-targeted imaging based on “optical” and “mag-

netic resonance” (MR) imaging

Development of innovative molecular probes based on

new principles for imaging of biological functions and

metabolisms

Social Value The use of innovative molecular probes

with new principles reduces the burden on patient

through optimal medical treatment based on early cancer

detection and malignancy diagnosis.

Economic Value Creation of the market for molecular

probes based on new principles for photoacoustic (PA)

imaging as well as probe-targeted focal magnetic reso-

nance (MR) imaging

Results to Date We have developed four kinds of highly

functional photoacoustic (PA) imaging probes based on

dye-containing nanoparticles by fusion of optical and

ultrasound imaging technologies. Otsuka Pharmaceutical

Co., Ltd. has participated in this project to accelerate the

pre-clinical trials of them. On the other hand, we have

succeeded in developing 13C/15N-labelled poly(2-meth-

acryloyloxyethylphosphorylcholine), 13C/15N-PMPC, probe,

which accumulates

very selectively and ef-

ficiently in the tumour

b y t h e e n h a n c e d

permeability and re-

tention (EPR) effect,

and realizes the first

probe-targeted focal

4 Development of Molecular Probes

Collaborating Organizations : Canon Inc., Otsuka Pharmaceutical Co., Ltd.

New Optical Coherence Tomography Equipment (OCT-HS100)

An Image of the Breast Cancer Examination with PAM

600 billion yen (global market scale) /4 years after end of

Results to Date We have developed the state-of-the-art

atomic magnetometers achieving the top level sensitivity

in the world. We also have developed a compact mod-

ule-type atomic magnetometer. Using the atomic mag-

netometers, NMR signals have been observed under low

magnetic field conditions. In addition, both the imaging

of magnetocardiographic distributions and the measure-

ment of neuro-magnetic fields

are successful in humans.

A Module-type Atomic Magnetometer

A Photoacoustic-Magnetic Resonance Dual Im-aging Probe

Collaborating Organization : Canon Inc.

Aspect Analysis Based on the Features of Lung Nodule

rs for A

s Prog

The University of TokyoCOE for Nano Quantum Information Electronics

ORGANIZATION

Name The University of Tokyo

U R L http://www.nanoquine.iis.u-tokyo.ac.jp/index-e.html

Address 4-6-1, Komaba, Meguro-ku, Tokyo TEL. 03-5452-6920 FAX. 03-5452-6921

Development of technologies to realize a safe, low energy consumption, and ambient IT society through a combination of nanotechnology, quantum science, IT, and electronics

Overall Person-in-charge Junichi Hamada (President, the University of Tokyo)

Researcher (Representative) Yasuhiko Arakawa (Professor, Institute of Industrial Science)

2 Overall Concept

B y t h e d e v e l -

opment of in-

novat ive bas ic

technologies and

the nu r tu r i ng

of research manpower, we aim to realize a

next-generation information network system

that satisfies the ultra-broadband, ultra-safe

and ultra-energy-efficient (low power con-

sumption) requirements of the ubiquitous

information society of the future.

Within the university we are consolidating

knowledge on nanotechnology, quantum

science, and IT, and striving to build up both

international and national collaborations

with influential researchers and institutions

within and outside Japan. Our core research

is being carried out on next-generation nano-

electronics, focusing on quantum dot lasers,

nano-quantum information electronics such

as encrypted quantum communications, and

the basic technologies in quantum informa-

tion science that support all of these areas.

Advanced lectures that provide a broad over-

view of these topics are given in the science

and engineering schools, and intensive indus-

try-orientated lectures are organized with col-

laborating organizations in order to develop

well-rounded personnel.

Intellectual property agreements among the

collaborating organizations are unified, and

we are also carrying out Intellectual property

reform making use of special zones within the

university. We are striving to attract excellent

researchers to the center.

1 Expand the market for quantum dot lasers and build a foun-

dation for the creation of innovation using quantum mechanical

devices.

2 Verify the high-speed behavior of organic CMOS circuits

and establish the basic technologies for large-area organic

electronics.

3 Achieve quantum key distribution over long distances (i.e., a

transmission distance of 50 km) using single-photon technologies

and demonstrate commercialization possibilities for encrypted

quantum communications.

1 Expand the market for industrial and consumer applications of

quantum dot lasers beyond telecommunication technologies.

2 Establish technologies for low-voltage, high-speed organic

CMOS circuits, large-area organic electronics, and high-durability

organic transistors.

3 Verify the possibility of increasing the efficiency of solar cells

using quantum dots (creating innovative technologies in renew-

able energy).

1 Achieve greater mass production and market expansion for

quantum dot lasers, and an enlargement of the business scope

for optical electronics including silicon photonics as core devices.

2 Expand the market for organic electronics products.

3 Commercialize single-photon quantum key distribution tech-

nologies that guarantee absolute safety within a metropolitan

network (~100 km).

Collaborating Organizations : Sharp Corporation, NEC Cor-

poration, Hitachi, Ltd., Fujitsu Laboratories Ltd., QD Laser, Inc.

RESEARCH THEME

Research and development on increasing the output,

speed, and performance of quantum dot lasers for com-

munication purposes is on-going. Research and devel-

opment on other applications besides communications

is also being conducted. Such applications include sol-

id-state laser excitation light sources for material process-

ing, sensor light sources for application at high tempera-

ture (200°C), high-output/high-speed modulated green,

yellow-green, and orange visible semiconductor lasers

using second harmonic generation (SHG), and lasers for

optical connections between LSI chips, etc.

Social Value Due to their low cost, low power con-

sumption and excellent temperature stability, quantum

dot lasers will facilitate environmental friendly operation

and hence provide competitive strengths for investment

in communications infrastructure.

Economic Value A new business model can also be

found in using cheap GaAs substrates, consumer man-

ufacturing lines, EMS, etc., with the possibility of tak-

ing over the current market for quantum well lasers.

About 100 billion yen (global) 3 years after the end of

the implementation period

Results to Date For communication applications, lasers

with a maximum modulation speed of 25 Gbps and are

stable up to temperatures of 20–70°C have been pro-

duced. For sensing applications, compact visible laser

modules (0.5 cc) that

can work at temper-

atures up to 220°C

a n d h i g h - o u t p u t ,

high-speed green la-

sers that exceed 100

mW in power have

also been realized.

The University of TokyoCOE for Nano Quantum Information Electronics

1 Development and deployment of quantum dot laser technologies

3 Development of basic technologies for high efficiency quantum dot solar cells

High efficiency energy conversion is expected for quan-

tum dot solar cells, and systematic research and devel-

opment starting with basic areas such as new materials,

nanostructures, and functionalities are being carried out

(with a focus on using the intermediate band) in order to

investigate theoretical possibilities.

Social Value Raising the conversion efficiency above a

certain level will put a stop to the current cost compe-

tition and usher in a paradigm shift when quantum dot

solar cells are built into mobile devices, OA equipment,

cars, and the like.

Economic Value Create new value and cost competitive-

ness, leading to an expansion in the market base for so-

lar power generation.

About 1 trillion yen (global) 15 years after the end of the

Results to Date A basis study of quantum dot solar cells

has been conducted. Previously, the highest theoretical

efficiency limit was thought

to be 63%, but this has

been updated to 75% in

theory. A prototype quan-

tum dot model achieved a

maximum of 18.7% and

demonstrated for the first

time that there is no de-

terioration when realizing

flexibility.

2 Organic CMOS circuits that achieve high speeds with low power consumption

Silicon semiconductors are the main type of semiconduc-

tors in current use. Organic semiconductors may be more

flexible, cheaper, and advantageous, although there is

a need to overcome the low speed and high voltage re-

quired before market expansion can take place. In order

to create organic CMOS circuits, a variety of technolo-

gies (starting with basic technologies) are currently being

accumulated.

Social Value Organic circuits are flexible and cheap, and

once their performance reaches a higher level, they will

begin to appear in consumer-related products. Following

this, products including drive circuits such as displays will

use only organic semiconductors.

Economic Value As today’s development of semicon-

ductors relies on silicon CMOS, compatibility with this

technology will enable the realization of high-speed,

low-power-consumption organic circuits, which will in

turn create new markets.

About 2 trillion yen (global) 5 years after the end of the

Results to Date Using a p-type pentacene organic TFT

and the increased mobility in n-type C60, a 5-step CMOS

ring oscillator with a cut-off frequency exceeding 200

kHz has been achieved (this

value is the highest in the

world, and is sufficient for

use in RFID). A low-cost

so lu t ion manufactur ing

method for C60 has also

been developed.

Quantum dot solar cells

Quantum key distribution technology using single photons in the communi-

cations wavelength band

Collaborating Organizations : Fujitsu Laboratories Ltd., QD Laser, Inc.

Quantum dot laser

Organic CMOS circuit

Collaborating Organizations : Sharp Corporation, NEC Corporation

Collaborating Organizations : Sharp Corporation

Collaborating Organizations : NEC Corporation, Hitachi, Ltd., Fujitsu Laboratories Ltd.

A Quantum key distribution technology using single pho-

tons in the 1.5 μm band with performance that is top of

its class has been achieved by the promotion of open in-

novation that transcends the barriers among competing

companies, and collaboration with NICT (National Insti-

tute of Information and Communications Technology).

Social Value Compared to quasi-single photon meth-

ods, this method is able to simplify system configuration

and safety analysis by a wide margin, and will result in

a breakthrough in the commercialization and spread of

quantum cryptography communication.

Economic Value The economic impact from ensuring the

absolute safety and reliability of communications will be

enormous.

About 40 billion yen (global) 5 years after the end of the

Results to Date The multi-photon occurrence rate,

which determines whether or not eavesdropping is possi-

ble, has been limited to 1/500 of the classical light ratio.

Single photon generation in the 1.5 μm band with the

highest purity in the world has been achieved. Together

with a superconducting detector, a new quantum cryp-

tography system has been developed, and quantum key

distribution tests that exceed 100 km (twice the previous

range) have been successfully conducted.

Development of single-photon quantum cryptography distribution technologies in the com-munications wavelength band

rs for A

s Prog

Hokkaido UniversityThe Matching Program for Innovations in Future Drug Discovery and Medical Care

ORGANIZATION

Name Hokkaido University

U R L http://www.cris.hokudai.ac.jp/cris/innovahome/index_e.html

Address Kita-8, Nishi-5, Kita-ku, Sapporo-shi, Hokkaido TEL. +81-(0)11-706-9188 FAX. +81-(0)11-706-9190

Fusion of next-generation drug discovery using protein modification technologies and personalized medicine using light and radiation measurement technologies

Overall Person-in-charge Keizo Yamaguchi (President, Hokkaido University)

Drug Discovery Research Project Leader : Yasuyuki Igarashi (Specially Appointed Professor, Frontier Research Center for Post-genome Science and Technology ) / Medical Care Research Project Leader : Nagara Tamaki (Professor, Graduate School of Medicine)

Collaborating Organizations : Shionogi & Co., Ltd., Hitachi,

Ltd., Sumitomo Bakelite Co., Ltd., Nihon Medi-Physics Co.,

Ltd., Mitsubishi Heavy Industries, Ltd.

Establish basic technologies for drug discovery such as new li-

gand screening technologies, etc., and multiple pharmaceutical

candidate compounds, and identify disease-related biomarker

candidates. Link advanced life sciences to medical device engi-

neering as well as medical personnel in hospitals to companies in

equivalent positions for future drug discovery and interdisciplin-

ary medical centers. Relevant areas include RI molecular probe

exploration, quantitative diagnosis using semiconductor PET, and

radiation therapy plan combining PET images with other modali-

ty images.

Link up with university hospitals, support organizations for trans-

lational research and chemical compound libraries, etc., build a

platform that will serve as a foundation for next-generation drug

discovery research and medical device development, create “fu-

ture drug discovery and medical care centers” (provisional name)

for R&D that private companies cannot undertake on their own,

promote technology transfers between industry and academia,

and generate new innovations in a sustainable manner.

Make use of new technologies to establish a system for the con-

tinuous creation of next-generation pharmaceutical candidate

compounds that meet clinical needs. Establish a translational

research system for clinical evaluation of the usefulness of new

drug candidates, RI probes, biomarkers. Realize new personal-

ized medicine that is beneficial for patients based on these inno-

vations.

2 Overall Concept

Create an international center for human re-

sources development and research focusing

on a gateway to establish a foundation for

drug discovery that enables potential drug

candidates to be created continuously, and to

realize non-invasive personalized medical care

that is beneficial to patients. Link interdisci-

plinary research on life sciences and advanced

medical engineering to advanced medical

treatment, promote system reform in con-

nection with the university’s involvement in

development work, and streamline the drug

discovery and medical device development

process. Promote independent research and

development that is difficult for individual

companies to undertake due to the large risks

involved. Develop young, exit-oriented young

researchers by employing those from both

within and outside Japan and by employing

corporate researchers as graduate school

lecturers, faculty staff, etc. Implement vari-

ous system reforms to encourage corporate

researchers to obtain postgraduate degrees,

and also promote mutual personnel exchange

between industry and academia. Organize

international symposiums on a regular basis

and promote interdisciplinary research with a

global outlook.

Researcher (Representative)

RESEARCH THEME

Hokkaido UniversityThe Matching Program for Innovations in Future Drug Discovery and Medical Care

Integrating PET technology with image- guided radiation therapy equipment

Results to Date A product concept for the parallel

plane, PET-mounted radiation therapy equipment that

allows cancer imaging to be

carried out during treatment

by combining an X-ray therapy

machine with a PET machine

has been established.

Social Value Build a new foundation for drug discovery

and the development of diagnostic and therapeutic de-

vices through manpower exchanges and interdisciplinary

research in personalized medical care using next-gener-

ation drug discovery and photonic/RI imaging technolo-

gies, and contribute to improvement in the patient quali-

ty of life and treatment results for diseases.

Economic Value The greatest economic value lies in the

university being able to take the lead in undertaking

research and development that is deemed too risky for

individual companies to embark upon, and this value

cannot be quantified. To penetrate the markets envis-

aged below, while realizing product development based

on the technologies cultivated in the innovation center, a

process that extends from R&D all the way to clinical ap-

plications via translational research is also being realized

within a single university campus. Doing so will further

increase the economic value for collaborating organiza-

tions to choose a university in Japan rather than an over-

seas facility as a platform partner.

Infectious disease and metabolic diseases drugs: 250–

500 billion yen/8–12 years after end of implementation

period; glycan microarray: 2.5 billion yen in 2030; PET/

SPECT; 15–230 billion yen in 2030; new RI probe: 4–5

billion yen in 2030; radiation therapy equipment: 72–78

billion yen in 2030

Human Resources Development Capable personnel with a

thorough understanding of life science, drug discovery,

medicine, and other areas who are able to work as lead-

ers in multidisciplinary research areas are being cultivated

in the university and companies. Foreign researchers and

researchers from collaborating organizations developed

at this center are working as specially appointed pro-

fessors or company management, and the number of

invitations extended to the center’s researchers to give

lectures at international conferences as well as the num-

ber and size of developmental research grants acquired

are increasing.

Collaborating Organization : Mitsubishi Heavy Industries, Ltd.

4 Research and development on new RI probes

Results to Date In response to the PET innovation, a

new RI probe has been developed, and R&D using animal

disease models is in progress. A bridge towards clinical

applications has been built within the university, allowing

clinical evaluation to be carried out in collaboration with

research and support organizations.

Collaborating Organization : Nihon Medi-Physics Co., Ltd.

Towards the establishment of a drug discovery foundation that enables the continuous creation of potential drug candidate compounds

Make use of the strengths of Hokkaido University in researches of lipids, glycans, structural biology, etc., to explore new

potential drug targets, conduct drug discovery research based on advanced protein structures, promote investigative re-

search and development of research tools for identifying diseases and creating biomarkers for drug discovery, and take

on the challenge of creating potential pharmaceutical compounds that can advance to the clinical trial stage, with the

ultimate aim of establishing a drug discovery foundation that enables the continuous creation of potential drug candidate

compounds. In addition, expand basic and clinical research with a focus on the development of regenerative medicine.

Collaborating Organization : Hitachi, Ltd.

Development of non-invasive personalized medical care beneficial to patients

Based on component technologies such as photonic/RI imaging technology, aim for the construction of a new medical

process and development of medical devices that make non-invasive personalized medical care that is beneficial to patients

a reality, and take up the challenge of conducting R&D in various areas in partnership with collaborating organizations.

Results to Date The use of the virus library in Hokkaido

University contributed to the development of anti-influ-

enza drugs launched in 2010. Based on the results ob-

tained in this project, one potential drug compound has

also entered pre-clinical trial testing. Besides this, three

new drug discovery programs

have also been started (for two

infectious disease drugs and

one lifestyle-related disease

drug). Furthermore, drug dis-

covery group has started a bio-

1 Development of pharmaceutical products with new action mechanisms

2 Development of new carbohydrate microarray

Results to Date Based on the

results obtained in this project,

Sumitomo Bakelite Co., Ltd.

started sales of a carbohydrate

microarray in FY2011.Collaborating Organization : Sumitomo Bakelite Co., Ltd.

Collaborating Organization : Shionogi & Co., Ltd.

marker exploration project with Shionogi & Co., Ltd. that

is spearheaded by its wholly owned U.S. subsidiary Ezose

Sciences, which was established in Feb 2009.

Results to Date Research that applies semiconductor

technology in medical treatment has been advanced

through the development and clinical application of the

world’s first PET/SPECT that uses a semiconductor de-

tector. Due to the high-definition of the detector, local

diagnosis of the hypoxia region in head and neck cancer

is made possible, and this has been applied in radiation

therapy planning. As a ripple effect, this has also proven

useful in the detection of radia-

tion after the Great East Japan

Earthquake and the commercial

sales of semiconductor radiation

detectors and modules.

Development of high-definition PET/SPECT using semiconductor detection technology, and related clinical applications

rs for A

s Prog

Tokyo Women’s Medical UniversityAdvanced Interdisciplinary Center for the Establishment of Regenerative Medicine

ORGANIZATION

Name Tokyo Women’s Medical University

U R L http://www.twmu.ac.jp/ABMES/CSTEC/ja

Address 8-1, Kawada-cho, Shinjuku-ku, Tokyo TEL. 03-3353-8111 FAX. 03-3359-6046

Creation of innovation centers for the development, spread, and industrialization of world-leading and multi-disciplinary regenerative technology through the fusion of cell sheet engineering technology and medical science

Overall Person-in-charge Hiroshi Kasanuki (President, Tokyo Women’s Medical University)

Researcher (Representative) Teruo Okano (Professor, Tokyo Women’s Medical University)

Collaborating Organizations : Dai Nippon Printing Co., Ltd.,

CellSeed Inc., Hitachi, Ltd.

1 Carry out the world’s first human clinical research on cell sheet

regeneration for esophageal cancer, heart failure, periodontal

disease, pneumothorax, and the like, in addition to achieving the

world’s first approval for cornea regeneration using cell sheets.

2 Establish a manpower development and support system with

on-the-job trainings of new types of regenerative medicine doc-

tors and researchers based on a new setup for industry-academia

collaboration and interdisciplinary medical engineering.

1 Regenerative medicine using cell sheets for a variety of tissue

and internal organs will be made available to patients at clinical

sites, including those overseas.

2 A regenerative medicine industry using cell sheets to achieve

radical treatment will pull along the pharmaceutical industry and

achieve greater development through the fusion of advanced

technologies and new fields.

1 Promulgate the use of cell sheets worldwide in addition to

promoting clinical research and clinical trials in regenerative

medicine using cell sheets for various tissue and internal organs.

2 Achieve a breakthrough that exceeds traditional boundaries

in 2D tissue cultivation and establish the basic technologies for

realizing organ regeneration after tissue regeneration. Promote

the sharing of ideas, technologies, and aims among doctors and

researchers and create industrial innovations for a society that is

based on regenerative medicine using cell sheets.

2 Overall Concept

Regenerative medicine is attracting much

attention as a next-generation radical cure

amid heightening expectations for treatments

to substantially improve the QOL of patients

suffering from serious ailments and intrac-

table diseases. This center aims to become

a research center for creating innovations

that integrate various advanced technologies

across different domains deemed necessary

for making regenerative medicine truly feasi-

ble. We have already created “cell sheet engi-

neering,” and after verifying its effectiveness

and safety in animal experiments, we have

been successful in treating the ailments of

patients. This socially and medically unprece-

dented treatment method has been achieved

through the combined efforts of many re-

searchers and doctors in different domains,

and a next-generation, interdisciplinary

medical engineering center that has hitherto

not been seen has been formed. In order to

further develop and spread this innovation,

industrialization through mass production

and generalization of the existing system is

necessary. Further manpower development

and building of international competitiveness

is aimed for, together with the collaborating

organizations.

RESEARCH THEME

3 Development of support technologies for medical treatment using cell sheets

Develop highly functional cell cultivation medium, auto-

matic culture apparatus, and cell sheet transplant devic-

es, etc., that are necessary to realize true regenerative

medicine based on a fusion of cell sheet engineering and

cutting-edge technologies owned by collaborating or-

ganizations, as well as establish support technologies for

regenerative medicine so as to implement the cell sheet

production process and transplant process safely and ef-

ficiently.

Social Value Overseas sales of a temperature-respon-

sive culture dish were started via the U.S. company Ther-

mo Fisher Scientific in Nov 2008 (see figure). By further

developing automatic culture apparatus and transplant

devices, regenerative medicine technologies can prolifer-

ate rapidly.

Economic Value These technologies all aim to realize cell

sheet treatment at an industrial level, and the econom-

ic value brought about by these mediums and devices

which are required for widespread proliferation of the

technologies is expected to be high.

Temperature-responsive culture dish: 33 billion yen/5

years after end of implementation period; automatic

culture apparatus: 4.5 billion yen/10 years after end of

implementation period, cell sheet transplant device: 6.0

billion yen/10 years after end of implementation period

Results to Date Technology that can produce a tem-

perature-responsive culture dish with high efficiency has

been established through a tie-up between Dai Nippon

Printing Co., Ltd. and CellSeed Inc. In addition, Hitachi,

Ltd. has also produced a prototype of an automatic cul-

ture apparatus that meets GMP requirements. Stable

production of cell sheets using this equipment has been

verified with the cooperation of Tokyo Women’s Medical

University.

Tokyo Women’s Medical UniversityAdvanced Interdisciplinary Center for the Establishment of Regenerative Medicine

1 Clinical application using a variety of cell sheets and development of peripheral projects

We believe it is our duty to overcome illnesses that cur-

rently cannot be cured by conducting clinical research

based on achievements in basic research to verify effec-

tiveness and safety. Having developed the world’s first

treatment method using cell sheet engineering in Japan,

we aim to spread the use of this treatment method Ja-

pan worldwide.

Social Value By realizing and spreading the use of

regenerative medicine, it is possible to reduce medical

costs in addition to markedly improving the QOL of pa-

tients.

Economic Value The cornea, myocardium, esophagus,

and periodontal market exceeds 1 trillion yen worldwide,

and thus the economic impact will be great if these

illnesses can be cured using cell sheet engineering.

Cornea: 4.5 billion yen/3 years after end of implementa-

tion period; esophagus: 60.4 billion yen/5 years after end

of implementation period: Periodontal: 17.3 billion yen/5

years after end of implementation period

Results to Date Clinical research using cell sheets has

started in Japan in various domains such as the cornea,

heart, esophagus, periodontium, and cartilage in accord-

ance with the ‘Guidelines on clinical research using hu-

man stem cells’. Clinical trials on the regeneration of the

esophagus have been completed in Japan and overseas

expansion has been started together with the transfer

of technology to the Karolinska Institute in Sweden. In

order to build the foundation and the popularization of

cell sheet treatment, clinical research using autologous

oral mucosa cell sheets transported over long distances

from the Tokyo Women’s Medical University has begun

in Nagasaki University.

2 Basic research using a variety of cell sheets

The establishment of a drug discovery evaluation model

for heart diseases and the production and transplant of

myocardium tubes, pancreatic sheets, liver cell sheets,

and the like for the treatment of Type I diabetes, haemo-

philic diseases, and other ailments are underway as basic

research using cell sheets. New uses for hematopoietic

stem cells that are expected to be a cell source are also

being developed for regenerative treatment.

Social Value A drug discovery evaluation model using

myocardium tubes can be used for ex vivo drug discovery

evaluation. Pancreatic and liver cell sheets will also free

patients suffering from Type I diabetes and haemophilia

from drug administration and

help reduce medical costs.

Economic Value T h e g l o b a l

market for heart disease treat-

ment drugs is said to be 380

billion yen, and thus the eco-

nomic effect will be large if

myocardium tubes can be used

as a drug discovery evaluation

model. In the case of diabetes and hemophilia, frequent

drug administration will become unnecessary, and thus

the QOL of patients can be improved together with a

Collaborating Organizations : CellSeed Inc.

substantial reduction in medical costs.

Myocardial tubes: 38 billion yen/3 years after end of im-

plementation period; liver, pancreas, hematopoietic stem

cells: 10 billion yen/10 years after end of implementation

period

Results to Date Through the extension load on the tu-

bular myocardial tissue produced in vivo, an increase in

expression in the swelling of the myocardial cells and

vascular endothelial growth factor due to this can be ob-

served to a significant degree. Myofibrillar formation and

developed mitochondria can be observed as well. After

transplanting pancreatic cell sheets subcutaneously into

mice that have developed diabetes, it was observed that

the blood sugar level had normalized in all cases.

Collaborating Organizations : Dai Nippon Printing Co., Ltd., CellSeed Inc., Hitachi, Ltd.

Collaborating Organizations : CellSeed Inc.

Myocardium tube

pancreas liver

In-Depth Focus 04 Tokyo Women’s Medical University

In-Depth Focus 03 Hokkaido University

In-Depth Focus 02

In-Depth Focus 01 Kyoto University

The University of Tokyo 東京大学The University of Tokyo

New Imaging-Diagnosis Equipment — Optical Coherence TomographyThe research group’s breakthrough in Optical Coherence Tomography

(OCT), simultaneously bringing further improvements in resolution and

imaging speed, the OCT-HS100 marketed by Canon in Sep. 2012, is

expected to lead to a high level eye fundus diagnostic modality with the

ability to detect signs of sight threatening diseases appearing on the

fundi.

Clinical Research in Progress — Photoacoustic Mammography(introduced with a newspaper, the Nihon Keizai Shimbun, on June 29, 2010)The research group is investigating a novel technology which integrates

Ultrasound and optical imaging (US/PAT), and a prototype model of the

Photoacoustic Mammography (PAM) has been introduced at the Clinical

Research Center for Medical Equipment Development. A clinical study of

PAM, which enables the visualization of neovascular networks of cancer,

has been started to demonstrate its usefulness in the early detection and

functional diagnosis of cancer without X-ray irradiation.

The ultimate goal of the project is to create a “healthy society” by promoting cutting-edge research and development, improv-ing quality of life (QOL) and reducing medical expenses for the aging society, while fostering talented researchers in an inter-disciplinary research area of medicine and engineering.

New Optical Coherence Tomography Equipment (OCT-HS100)

An Image of the Breast Cancer Examination with PAM

Innovative Techno-Hub for Integrated Medical Bio-Imaging

COE for Nano Quantum Information Electronics

Establishment of the Shionogi Inno-vation Center for Drug DiscoveryThe Shionogi Innovation Center for Drug Discovery was established in 2008 by Shionogi & Co., Ltd. as a profes-sional center of collaboration between industry and academia to nurture the seeds of technology sown by Hokkaido University and discov-er future drug discovery prospects. This 5-story center with a building area of 600 m2 and a floor area of 2,790 m2 is the first research facility from the private sector built within the grounds of a national university in Japan. Development of high-definition semiconductor PETThe clinical research system of Hokkaido University was en-hanced, and a total of about 680 clinical cases, which exceeded the number planned initially, were studied during the develop-ment of the high-definition semiconductor PET. The development framework has also been further enhanced through the devel-

Prototype models for semiconductor PET equipment and SPECT equipment used for brain

opment and introduction of a prototype semicon-ductor gamma camera in the Hokkaido University Hospital by Hitachi, Ltd., the commercialization of a radiation detector module, and other initiatives.Long-term human resources development for life sciencesEvery year, joint lectures for the Graduate Schools of Hokkaido University such as the “Shionogi Special Lecture on Drug Discov-ery Science,” the “Molecular Imaging Seminar,” and “Advanced Radiology, Nuclear Medicine, and Radiation Oncology” are conducted by more than 80 researchers from collaborating com-panies. This far, about 500 graduate students have attended the lectures in the last 5 years. A center for continued cooperation with the companies in developing such long-term manpower for the life science sector is also being formed.Advanced Radiation Therapy Project: Real-time Tumor-tracking with Molecular Imaging Technique Professor Hiroki Shirato proposed joint research on proton beam treatment to Hitachi, Ltd., and they have been developed many equipment. He was also the core researcher of the Funding Program for World-Leading Innovative R&D on Science and Tech-nology (FIRST program) in FY2009 under the title “Advanced Ra-diation Therapy Project: Real-time Tumor-tracking with Molecular Imaging Technique” selected by the Cabinet Office as one.

Posters advertising on the joint lectures conducted by the graduate school in FY2013

Advanced Interdisciplinary Center for the Establishment of Regenerative MedicineCOE for Nano Quantum Information Electronics

rs for A

s Prog

rs for A

s Prog

Osaka UniversityPhotonics Advanced Research Center

ORGANIZATION

Name Osaka University

U R L http://www.parcjp.org/

Address 2-1, Yamada-oka, Suita, Osaka TEL. 06-6879-7927 FAX. 06-4864-2695

Development of emerging industrial technologies in the 21st century from the fusion of photonics technology with nanotechnology and biotechnology

Overall Person-in-charge Toshio Hirano (President, Osaka University)

Researcher (Representative) Satoshi Kawata (Professor, Graduate School of Engineering)

Implementation Period FY2007 – F Y2016

Collaborating Organizations : Shimadzu Corporation, Sharp

Corporation, Nitto Denko Corporation, Mitsubishi Chemical

Group Science and Technology Research Center, Inc., IDEC

Corporation

Create prototyping models out of core technologies for inno-

vation such as bio-optical materials, optical control devices,

petabyte optical recording technologies, bioimaging/diagnosis

systems, and ubiquitous sensing systems, and evaluate the possi-

bility of industrializing them.

Aim to create a research and development center for photonics

technology that is top of its class in the world. Build an unpar-

alleled industry-academia equal partner system that promotes

joint operations and R&D between Osaka University and industry

partners. And combine developmental phases in the commer-

cialization and industrialization process with output oriented

R&D starting from basic research in photonics. Innovations in

nanophotonics and plasmonics promoted through this center are

advanced themes in the whole photonics field that will serve as

a leading foundation for green and life innovations in the 21st

century and lead the world in science, technology and industry.

Aim to create and commercialize more than 20 products, among

developmental projects for commercialization and industrializa-

tion. Build an unprecedented interpenetrating partnership system

between industry and academia providing an interdisciplinary

environment in which people, technology, and space are joined

to form a melting pot for innovation. This system is expected to

churn out great numbers of personnel who excel industrializing

advanced science and technology and preeminent R&D achieve-

ments.

2 Overall Concept

Osaka University has established a new pho-

tonics research center to create photonics

innovations in collaboration with five indus-

try partners. Photonics is an interdisciplinary

academic domain that extends across a wide

range of fields such as physics, chemistry,

bioscience, materials science, electronics engi-

neering, and mechanical engineering. More-

over it is a base for cutting-edge technologies

such as nanotechnology, biotechnology, IT,

environmental technologies, and energy tech-

nologies.

As a global research center for photonics,

this center promotes interdisciplinary research

that cuts across academic barriers and scien-

tific societies ones through an interpenetrat-

ing partnership system that serves as a new

industry-academia collaboration model. We

develop PhD students who are leading pho-

tonics science and industry internationally.

RESEARCH THEME

Osaka UniversityPhotonics Advanced Research Center

1 Eco Energy: Portable organic solar cells and highly sensible LEDs

Realize low-cost, long-life, light, and highly efficient or-

ganic thin film solar cells with organic semiconductors

that can be coated to form a film and proven to be ro-

bust and stable. Develop fluorescent materials to form

quantum dot to realize LED lighting technology that

saves energy and is also friendly to humans and the en-

vironment and contribute to improvements in safety and

security by counterfeit prevention technologies.

Social Value Bring about innovations in the eco en-

ergy field by commercializing portable emergency re-

sponse-type, independent, and decentralized energy

sources. Expedite the full replacement of conventional

lights with highly sensible LED lighting and ensure safety

and security in security applications.

Economic Value Secure a market for portable highly re-

liable, high-value-added solar cells. Ensure international

competitiveness using highly sensible, high-quality LEDs

and protect safe and high-quality commercial products

through counterfeit prevention technologies.

Organic Solar cells: 12.8 billion yen in 2020; LED lights,

etc.: 5.5 trillion yen in 2020

Results to Date A conversion efficiency of 7% has been

attained for organic thin film solar cells and aiming to

produce larger devices. Elements with the world’s high-

est carrier mobility and energy conversion efficiency

higher than 3% have been

successfully developed in

coating-type, low molec-

ular, phthalocyanine solar

cells. Non-toxic semicon-

ductors quantum dot with

a high fluorescence quan-

tum yield that have been

developed at this center

has been applied to LEDs

and security.

Health & advanced medical devices: Biosensor, bio-imaging device, and nanospectroscopy mi-croscope

Develop multi-functional organic film biosensors for

managing human health, a new near-infrared fluorescent

probe (reagent) for the detection of enzyme activity that

will become a cornerstone of next-generation optical

diagnosis technology, a laser microscope for microscopic

observations of physiological phenomena in a live state,

and a nanometer microscope that allows DNA to be seen

using light.

Social Value Realize a healthy society that allows for

longevity through innovations in point-of-care systems,

early diagnosis, and devices for advanced medical/biolog-

ical research.

Economic Value Maintain an international lead and se-

cure international competitiveness for equipment and

products in the health and advanced medical device

fields.

2.31 trillion yen in 2020

Results to Date Basic tests on the detection of markers

in lifestyle diseases such as hypertension, Alzheimer’s

disease, and diabetes have been carried out using mul-

tifunction organic film biosensors and product develop-

ment is ongoing. The image contrast of the microscopic

structure and spatial resolution of the laser microscope

for observing physiological phenomena have been im-

proved, and patents to establish the technologies to

commercialize the optical nanometer microscope have

been acquired. An enhanced cutting-edge Raman scat-

tering microscope has been made into a commercial

product. Gas chromatography with a markedly improved

sensitivity has also been developed as applied research

in plasma photonics, and this product is now being sold

worldwide.

Develop optically assisted magnetic recording technolo-

gies with plasmons optical enhancement at a metal tip

by two orders of magnitudes, and thin film magnetic

materials. Develop crystal for high-output ultraviolet la-

sers required for next-generation precision processing of

electronic devices and semiconductor processing.

Social Value Seize the international initiative in devel-

oping high density recording media that realizes a sub-

stantial improvement in saving energy used by IT devices.

Lead in manufacturing evaluation for next-generation

LSIs and precision processing of next-generation elec-

tronic devices.

Economic Value Ensure international competitiveness in

high density recording technologies. Maintain a global

share of the market for next-generation evaluation devic-

es for semiconductor manufacturing and manufacturing

equipment for precision electronic devices.

High capacity optical storage: 26 trillion yen in 2020;

next-generation precision evaluation and processing

equipment: 2.7 trillion yen in 2020

Results to Date We developed thin film formation of

MnZn ferrite, a soft magnetic material that allows light

to pass through and is crucial magnetic head material for

optically assisted recording in next-generation magnetic

storage systems and analysed magnetization inversion

mechanism of the film. We have also successfully grown

the crystals for high-quality and high-power next-genera-

Collaborating Organizations : Mitsubishi Chemical Group Science and Technology Research Center, Inc., IDEC CORPORATION

Collaborating Organizations : Nitto Denko Corporation, SHIMADZU CORPORATION

tion ultraviolet lasers at a practical level and promoted to

commercialize it.

Collaborating Organizations : Sharp Corporation

Next-generation energy-saving, high-capacity optical storage and wavelength-conversion crys-tals for next-generation UV Laser for use in precise device- fabrication and semiconductor pro-cess-evaluation

rs for A

s Prog

rs for A

s Prog

The University of TokyoTranslational Systems Biology and Medicine Initiative

Development of minimally invasive, high-precision diagnosis and therapies through the fusion of integrated technologies in diagnosis and treatment with transformative technologies and antibody creation for cancer and lifestyle diseases

ORGANIZATION

Name The University of Tokyo

U R L http: //www.tsbmi.m.u-tokyo.ac.jp/index.html

Address 7-3-1, Hongo, Bunkyo-ku, Tokyo TEL. 03-5800-9079 FAX. 03-5800-9081 Overall Person-in-charge Junichi Hamada (President, the University of Tokyo)

Researcher (Representative) Takashi Kadowaki (Professor, Graduate School of Medicine)

1 Begin independent, doctor-led clinical trials for minimally

invasive, high-precision diagnostic and treatment equipment

using labelled antibodies based on the pre-targeting of cancer.

Complete animal trials for diagnostic and treatment systems that

combine antibody drugs with an HIFU (High-Intensity Focused

Ultrasound ) endoscope system.

2 Obtain pharmaceutical approval and commence sales for ex-

panded indications of diagnostic drugs for Type 2 diabetes and

complete independent, doctor-led clinical trials for low molecular

drugs.

1 Begin clinical trials based on the Pharmaceutical Affairs Act

for minimally-invasive, high-precision diagnostic and treatment

equipment using labelled antibodies based on the pre-targeting

of cancer. Enter into clinical trials based on the Pharmaceutical

Affairs Act for diagnostic and treatment systems that combine

antibody drugs with an HIFU (High-Intensity Focused Ultrasound)

endoscope system.2 Enter into independent, doctor-led clinical trials for antibody

drugs and clinical trials based on the Pharmaceutical Affairs Act

for low molecular drugs for Type 2 diabetes.

2 Overall Concept

This research aims at the

development of local-

ized treatment devices

and cell-specific drugs

against diseases in the

human body, as opposed to traditional inva-

sive medical devices and non-selective drugs

with many side effects. It is also a goal to

build a development center to provide safe,

secure, and compassionate medical treat-

ment. For these purposes, we will make use

of the features of the different missions that

companies shoulder in clinical research (pa-

tient specimens, access to information), basic

research (ability to obtain genes, cells, etc.;

theoretical and system operation capability)

and commercialization (ability to provide

funds for clinical trials and commercialization

technologies, etc.). We will break down the

traditional barriers inherent in one-to-one

joint research between universities and corpo-

rations and establish a new industry-academia

partnership system to advance research and

development in a cyclic manner from “clinical

to basic to commercialization to clinical.” This

will be achieved with the university acting as

platform for interdisciplinary research by the

university’s various laboratories, which possess

basic core technologies and information, and

numerous companies possessing world-lead-

ing elementary core technologies.

Collaborating Organizations : Forerunner Pharma Research

Co., Ltd., Olympus Corporation, Sekisui Medical Co., Ltd.,

Toray Industries Inc., Mitsubishi Tanabe Pharma Corporation,

Hitachi Aloka Medical, Ltd., Nikon Corporation, Kowa Compa-

ny, Ltd.

In addition to systematically and comprehensively identifying

cell-specific target proteins in cancer and lifestyle focal lesions

based on system disease life science, combine imaging using an

artificial protein probe with less invasive high-precision medical

device to integrate diagnosis and treatment at a low cost and

commercialize innovative drugs and treatment systems with few

side effects.

RESEARCH THEME

The University of TokyoTranslational Systems Biology and Medicine Initiative

1 Development of advanced medical technologies for treating cancer: Shortening treatment time

Besides labelling and creating antibodies against target

proteins from cancer cells and developing imaging tech-

nology that concentrates antibodies specifically at cancer

cells, integrate high-precision, less invasive diagnostic

and treatment methods for cancers with extremely high

specificity by developing an HIFU (High Intensity Focused

Ultrasound) endoscope using target antibodies.

Social Value Earlier cancer treatment becomes possible.

This will result in a drastic shortening in the treatment

time, while treatment methods that are less invasive will

allow treatment to be carried out on elder patients with

reduced physical strength, thereby substantially improv-

ing the QOL of patients in an ageing society.

Economic Value Through the use of endoscopic treat-

ment and less invasive, high-precision cancer treatment

technologies, treatment time is reduced by two-thirds or

more, making outpatient treatment possible. This will in

turn contribute to a large containment of medical costs.

The total market scale in 2025 (8 years after end of im-

plementation period) for diagnostic and treatment equip-

ment and treatment drugs is assumed as follows.

● Diagnostic and treatment equipment: Japanese mar-

ket : 7 billion yen ; global market: 90 million dollars

● Treatment drug: Japanese market: 30 billion yen;

global market: 1.95 billion dollars

Results to Date In the development of new treatments

for colorectal cancer using antibody drugs and HIFU (high

intensity ultrasound) endoscopes, antibodies for specific

cancer antigens (CCA1) found at this center have been

successfully created and used in humans. Furthermore,

technology to adorn phase-changing nano-droplets (re-

versible bubbling between the gas and liquid states using

ultrasound waves) in human antibodies has also been

developed. By combining such antibodies adorned with

phase-changing nano-droplets with the HIFU endoscope

developed at this center, it is possible to integrate less

invasive ultrasound diagnosis with pinpoint cancer treat-

ment through the creation of micro-bubbles (for killing

cancer cells) using ultrasonic irradiation and high-preci-

sion image diagnosis of deep areas in the body.

Development of advanced medical technologies for the treatment of lifestyle diseases : Con-trolling medical expenses for treating lifestyle diseases

Besides developing imaging technology for blood vessel

and arteriosclerosis diagnosis and the quantitative meas-

urement of visceral fats using less invasive, high-preci-

sion diagnostic and treatment device, drugs for the early

diagnosis and treatment of cancers using antibodies and

low molecular compounds against target proteins are

also being developed. Furthermore, fusion medical tech-

nologies created by optimizing a combination of these

two technologies are being developed as well.

Social Value Safe and secure diagnostic and treatment

technologies can be developed and supplied by decreas-

ing the economic burden and reducing disease complica-

tions through early diagnosis, thereby helping to reduce

the physical burden of patients in an ageing society.

Economic Value A 30% reduction in medical expenses

for treating lifestyle diseases can be realized.

The total market scale in 2025 (8 years after end of im-

plementation period) for diagnostic and treatment device

and treatment drugs is assumed as follows.

● Diagnostic device: Japanese market: 13.7 billion yen;

● Treatment drug: Japanese market: 10.5 billion yen;

Results to Date In the development of less invasive and

early diagnostic methods for metabolic syndromes (MS),

a system for measuring adiponectin with a high molecu-

lar weight, which is a key molecule in diabetes and MS,

has been developed. An early diagnostic method for MS

has been established and proven to be effective in the

early diagnosis of cardiovascular complications. By using

this as a companion diagnostic drug in personalized and

tailor-made medical applications, subject patients for ad-

iponectin receptor activators can be identified. Further-

more, quantitative measurement technology using less

invasive, high-precision abdominal ultrasound that over-

comes the shortcomings in the traditional quantitative

measurement of visceral fats has also been developed.

Accelerate “exit-oriented R&D” that aims to industrialize and commercialize products at an early stage and further cre-

ate new innovations in the development of novel, less invasive drugs and medical devices with fewer side effects and

lower costs in collaboration with eight participating companies.

Collaborating Organizations : Forerunner Pharma Research Co., Ltd., Kowa Company, Ltd., Olympus Corporation, Hitachi Aloka Medical, Ltd.Collaborating Organizations : Mitsubishi Tanabe Pharma Corporation, Toray Industries Inc., Sekisui Medical Co., Ltd., Hitachi Aloka Medical, Ltd., Nikon Corporation, Kowa Company, Ltd.

rs for A

s Prog

Tohoku UniversityR&D Center of Excellence for Microsystem Integration Research Initiative

ORGANIZATION

Name Tohoku University

U R L http://www.rdceim.tohoku.ac.jp/

Address 2-1-2, Katahira, Aoba-ku, Sendai-shi, Miyagi Prefecture TEL.022-717-7800 FAX. 022-229-4115

Development of micro-system hetero-integration technology using a combination of MEMS technology and LSI technology

Overall Person-in-charge Susumu Satomi (President, Tohoku University)

Researcher (Representative) Takahito Ono (Professor, Graduate School of Engineering)

Collaborating Organizations : Ricoh Company, Ltd., Top-

pan Technical Design Center Co., Ltd., Mems Core Co., Ltd.,

Kitagawa Iron Works Co., Ltd., Sumitomo Precision Products

Co., Ltd., Toyota Motor Corporation, The Nippon Signal Co.,

Ltd., Nidec Copal Electronics Corporation, Nihon Dempa Kogyo

Co., Ltd., Pioneer Corporation, MEMSAS Inc., Toyota Central

R&D Labs., INC., NIKKO Company, Japan Aviation Electronics

Industry, Ltd., Furukawa Electric Co., Ltd., Denso Corporation

1 Equip the established R&D center with shared facilities and

build up infrastructure, intellectual property, and Shared wafer

R&D systems.

2 Resolve various R&D issues related to the processing, equip-

ping, and installation of micro-systems that combine LSI and

MEMS technologies and establish the basic technologies required

for interdisciplinary research. Verify the functions of several com-

bined micro-systems and obtain an outlook for commercializa-

tion purposes.

1 Autonomously maintain a venue that supplies the best tech-

nologies, manpower, information, and opportunities at the most

suitable time and cost to society through private investment as

well as national and local investments.

2 Build a research center in which the R&D regarding combined

micro-systems and application products that are globally com-

petitive can be quickly carried out in an integrated fashion, from

design and elementary research to prototyping and commercial-

ization.

1 Continuously lead new technological development as an es-

tablished R&D center while partnering with various companies,

research institutions, and administrative bodies. Contribute to

the international competitiveness of relevant industries through

R&D related to micro-systems for future applications.

2 Supply developed interdisciplinary technologies for the com-

mercialization of products that are competitive in the market in

a variety of fields.

2 Overall Concept

Develop advanced micro-systems to support

a safe, secure, and wholesome social system

by combining cutting-edge LSI technologies

and MEMS technologies to create a paradigm

shift (“More than Moore”) that is sought

through LSI miniaturization. For that purpose,

R&D will be carried out among five research

groups (refer to the figure on the collabora-

tion system). Build a research center that will

generate strong industrial competitiveness

internationally by using the knowledge of

the university as a catalyst for industry-indus-

try-academia partnership, and by building an

open venue that is furnished with the nec-

essary reforms in infrastructure, intellectual

property (patent basket), and R&D systems

(Shared wafer system) to allow R&D to be

carried out jointly among multiple companies

and research institutions. Manpower devel-

opment to support this research center is also

being implemented by sending researchers to

overseas research institutions such as IMEC

based on a strategic partnership agreement

(the first in Asia), and by conducting intensive

courses and learning programs on MEMS that

are targeted at working adults.

Junichi Nishizawa Memorial Research Center

MEMS prototyping line

RESEARCH THEME

3 Golay cell-type integrated infrared sensor array

Infrared linear sensors for spectral measurement purpos-

es (e.g. environmental monitoring of greenhouse gases

and emission gases, monitoring of environmental con-

ditions in plant factories, safety monitoring in factories)

are being developed. Golay cell-type infrared sensors

that are sensitive in a wide range of wavelengths have

been integrated by being bonded onto an LSI made with

Shared wafer system.

Social Value In recent years, the need for an environ-

mentally-ubiquitous wireless sensor network to realize a

safe, secure, and clean society has heightened. Infrared

sensing is a means of environmental sensing. This sensor

is able to perform non-destructive measurements and

has the added advantage of being safe and not impact-

ing the human body at all.

Economic Value Use is possible in a wide range of appli-

cations, such as environmental conservation, security,

and consumer devices, and thus the economic value is

extremely high.

The global market for ultra-sensitive infrared detector

elements is expected to reach 260 million dollars in 2017

and 460 million dollars in 2023. Collaborating company

aims to enter the market in 2017.

Results to Date A Golay cell has been successfully min-

iaturized and made into an array using microprocessing

technologies. the infrared sensor array (Golay cell array)

mounted on top of an LSI designed and made with

Shared wafer system has been produced, and it has

demonstrated the ability to measure infrared radiation

with high sensitivity.

Tohoku UniversityR&D Center of Excellence for Microsystem Integration Research Initiative

1 Development of tactile sensors for robots

A full-body tactile sensor network system using MEMS-

LSI integrated devices for a life support robot has com-

bined characteristics such as low-power consumption,

small size, little wiring, interrupt communication, and

high-speed, high-precision sensing. Integration and

packaging of dedicated LSIs by our shared wafer system

and MEMS force sensors, that is a way to allow above

features, are being developed.

Social Value We aim to develop a robot that can safely,

securely, and pleasantly support human activities from

the sidelines, such as by keeping a watch over human

activities, or through gentle interactions with humans.

Economic Value Anthropomorphic robots (an area in

which Japan has an edge) are expected to spread through-

out Japan and the world. Instead of replacing the current

market, a significant feature of the technology lies in the

fact that a whole new market may be opened up.

The global market for life support robots is expected to

start from a scale of 100 million dollars per year in 2017

at the point of launch and then exceed 80 billion dollars

per year in 2031.

Results to Date A tactile sensor network system using

generic parts such as existing sensors and dedicated LSIs

with integrated MEMS force sensors on top has been

completed, and overall development of a system using

integrated devices is ongoing. An Outstanding Paper

Award was also given out at Transducer 2011, one of

the world’s most foremost international conferences in

the field.

2 Development of an integrated micro-biosensor system

We are developing a bioimaging and simultaneous multi-

ple analysis system applied in wide fields including med-

icine, environmental monitoring, and food industry. The

“Bio-LSI” is our current detection-type biosensing sys-

tem, which successfully carried out unprecedented high-

speed, high-sensitivity measurements.

Social Value Our unprecedented sensing technologies

potentially provide systems to guarantee safety and se-

curity in the medical, environmental, and food industries,

as well as platforms for replacements for animal tests in

pharmaceutical development, technologies to screen for

useful molecules in the engineering field, and tools for

investigating biological functions in the life science.

Economic Value Our research has significant economic

effect to provide a technology for safety and security in

the modern world, which is rapidly ageing and facing se-

rious environmental, health, and safety problems.

Collaborating Organizations : Toyota Motor Corporation, Toyota Central R&D Labs.,INC.

Collaborating Organizations : Sumitomo Precision Products Co., Ltd.

Collaborating Organizations : Toppan Technical Design Center Co., Ltd., Japan Aviation Electronics Industry, Ltd.

The global market for array-type micro-biochips for DNA

and protein detection is expected to reach 9.6 billion dol-

lars in 2016 and 18 billion dollars in 2020 and this center

aims to enter the market in 2017 at the end of the pro-

Results to Date We have developed a practical system

that can take current measurements at a high speed (18-

125 ms/400 point) and a wide range with high sensitivity

(from ±1 pA to ±100 pA). We successfully got images

showing activities of bio-molecules such as enzymes and

cell division markers with high sensitivity. Figure shows

the results of the real-time imaging for diffusion of hista-

rs for A

s Prog

Kyushu UniversityInnovation Center for Medical Redox Navigation

Combine the wisdom of the Kyushu University with the creativity of different industries to create an advanced interdisciplinary medical research areas

ORGANIZATION

Name Kyushu University

U R L http://redoxnavi.kyushu-u.ac.jp/english/

Address 3-1-1, Maidashi, Higashi-ku, Fukuoka-shi, Fukuoka Prefecture TEL. 092-642-6031 FAX. 092-642-6024Overall Person-in-charge Setsuo Arikawa (President, Kyushu University)

Researcher (Representative) Yoshiki Katayama (Professor, Graduate School of Engineering, Kyushu University)

Collaborating Organizations : JEOL Ltd., Shimadzu Corpo-

ration, Mitsubishi Tanabe Pharma Corporation, Taiho Pharma-

ceutical Co., Ltd., HOYA Corporation, Fuji Electric Co., Ltd.,

NOF Corporation, Kyushu Electric Power Co., Inc.

1 Verify the usefulness of endogenous molecular probe and clin-

ically relevant redox measurement technologies. Carry out a study

on the effectiveness of the system towards realizing minimally

invasive treatments using redox navigation system. Implement

improvements towards large-scale verification tests starting from

small-scale verification tests in the health support system.2 Study effectiveness for preventing the onset of and complica-

tions arising from diabetes, verify the usefulness of bio-markers for

predicting the effects of anti-cancer drugs, perform toxicity tests

of polymeric micelles on large animals, and carry out drug effect/

drug mechanism studies. Search for prognosis marker, clinical test

applicability of mass spectrometry.

1 Complete the development of clinically relevant redox imag-

ing system and apply it to pre-clinical trials. Produce a compact

surgery support system capable of working within the gantry of

an Overhauser effect MRI (ReMI) and combine it with a variety of

treatment systems. Carry out verification research through an ex-

tensive network.2 Establish the clinical usefulness of a new measurement system

for oxidative stress markers. Implement Phase II and Phase III clini-

cal trials for gene therapy including polymeric micelles. Complete

the development of a mass spectrometer for cytological diagnosis

and expand the market for mass spectrometry to clinical sites.

2 Overall Concept

This center aims to create an advanced in-

terdisciplinary medical research area for the

development of medicines and establishment

of early diagnosis and treatment methods for

redox-related diseases such as lifestyle-related

diseases, cancer, and neurological disorders.

The center adopts the common concept of

changes in the oxidation-reduction phenom-

enon in the human body (redox) as a possible

cause and exacerbation of various diseases.

The center advocates the concept of “redox

navigation,” which will lead to the diagnosis

and treatment of such diseases by measuring

and visualizing in vivo redox, and investigat-

ing affected area and disease mechanisms.

In order to achieve these aims, the collective

wisdom of Kyushu University in the medical,

pharmacological, agricultural, and engineer-

ing fields will be collated together with the

creative powers of various industries in the

medical, pharmaceutical, and analytical in-

struments fields. In addition, it will promote

industry-academia and industry-academia-in-

dustry partnerships through interdisciplinary

research among the group members and

cultivate human resources to drive the “bio-

redox navigation” research area.

1 This center will be taken over by the Incubation Center for Ad-

vanced Medical Science (ICAMS), where a variety of companies

and research institutions will gather to conduct advanced research

mainly on redox navigation in collaboration among the participat-

ing companies. A center of excellence where technologies can be

commercialized in a beneficial manner will be established.2 Develop outstanding young investigators through collaborative

research in the advanced interdisciplinary medical field and con-

tribute to the development of university research and corporate

research and business activity.

RESEARCH THEME

3 Creating the seeds for drugs to prevent the onset of diabetes and to treat diabetes complications

Use bio-redox analysis and diagnostic technology to

establish an integrated technology foundation for the

development of drugs and treatments to control the on-

set of and complications arising from diabetes. Sow the

seeds that will contribute to the clinical development of

drugs for clinical applications based on this technology.

Social Value Improve the QOL of diabetic patients by

searching for new drug discovery seeds that will help to con-

Kyushu UniversityInnovation Center for Medical Redox Navigation

1 Production of clinically conforming redox scanner

An Overhauser enhanced MRI (OMRI/ReMI) is an indirect

free-radical imaging system that is useful for measuring

in vivo redox. Therefore a high-sensitivity ReMI will be

developed for clinical applications. In addition, three el-

ementary technologies—a redox endoscope, a compact

surgery support system, and an image guided system—

will be developed and integrated to build a in vivo redox

surgery support system.

Social Value The number of patients and people at risk

of lifestyle-related diseases exceeds 10 million in Japan.

The discovery rate for superficial cancer in the gastroin-

testinal tract, etc. will be improved.

Economic Value Create a new market for new measure-

ment instruments. Drastically reduce the physical and

economic burden of patients.

Over 1 billion yen/5 years after end of implementation

period

Results to Date A clinically relevant prototype ReMI has

been produced. A ReMI receiver coil that can be inserted

into the forceps opening of an endoscope has been de-

veloped.

Collaborating Organizations : JEOL Ltd., Fuji Electric Co., Ltd., HOYA Corporation

Collaborating Organizations : Mitsubishi Tanabe Pharma Corporation

2 Establishment of pathological metabolomics using mass spectrometry for cytological diagnosis

Apply the Matrix-Assisted Laser Desorption/Ionization

(MALDI) method in the measurement of metabolites and

carry out technological development to achieve rapid

analysis for the establishment of a new domain in patho-

logical metabolomics based on a mass spectrometer sys-

tem for drug discovery research.

Social Value Enable pathological diagnosis to be carried

out rapidly using mass spectrometry.

Economic Value Stimulate the market for mass spectrom-

eter systems for cytological diagnosis that can be used at

clinical sites.

The market for mass spectrometry equipment used in

the analysis of related bio-molecules is expected to reach

27.5 billion yen 5 years after the end of the implementa-

tion period.

Results to Date In order to expand the market to cover

clinical sites, matrix development and software develop-

ment to turn the equipment into a general-purpose mass

spectrometry

s y s t e m f o r

cytological di-

agnosis have

been carried

Collaborating Organizations : Shimadzu Corporation

5 Development of anti-cancer agent and gene therapy carrier

A search for target molecules that will serve as the weak

points of the cancer cells and enhancement of the an-

ti-cancer effect is being carried out based on the action

mechanisms of existing anti-cancer agents. Development

of genetic treatment drugs containing polymeric micelles

for cancers that are hard to treat is also ongoing.

Social Value Develop a market and innovations in the

field of anti-cancer agents, DDS, and drug discovery.

Economic Value The economic value is expected to reach

several hundred billions of dollars if new drugs and treat-

ment methods targeting cancer are developed.

The market launch timing and revenue forecast is pend-

ing, s ince these wil l

differ according to the

t ype o f cance r and

stage.

Results to Date A study

on the examination method for predicting the effects

of cancer chemotherapy using redox imaging and me-

tabolomics is being conducted. Production of carriers to

introduce polymeric micelle genes has been carried out

at the experimental level, and GMP manufacturing devel-

opment has also been completed.

Development of a confocal endoscope using MEMS tech-

nology that was started as an interdisciplinary research

project by HOYA, Fuji Electric, and Kyushu University,

and a hyper spectral camera whose development was

started in consideration of clinical needs.

Social Value Minimally invasive treatment can be real-

ized with a surgery support system that includes redox

imaging.

Economic Value Reduce the physical and economic bur-

den on patients.

Over 1 billion yen/5 years after end of implementation

period

Results to Date Software development has been com-

pleted and collaboration with the Center for Advanced

Medical Innovation will be carried out for clinical re-

search. In addition, agreements have been concluded in

various Asian coun-

t r i e s to exped i te

the approval of the

medical device, and

verification tests will

also be conducted

overseas.

Collaborating Organizations : HOYA Corporation, Fuji Electric Co., Ltd.

4 Development of a redox endoscope

trol the onset of and complications arising from diabetes.

Economic Value Contribute to the development of drugs and

early treatment methods for lifestyle diseases (5–6 trillion yen)

Overall medical costs for lifestyle diseases are expected to

amount to several trillion yen. The timing for the market

launch is still pending, as these are still seed technologies

for drug discovery.

Results to Date Evidence demonstrating the ability to

suppress the progress of diabetic vascular complications

through anti-oxidation has been verified for the first time

ever. Based on treatment via a potential target, oxida-

tive stress improvements and kidney improvements have

been demonstrated for a diabetes model.

Collaborating Organizations : Taiho Pharmaceutical Co., Ltd., NOF Corporation

Mixed polymer

rs for A

s Prog

ORGANIZATION

Name Kyoto University

U R L http: //www.ak.med.kyoto-u.ac.jp/

Address Yoshida Konoe-cho, Sakyo-ku, Kyoto-shi, Kyoto TEL. 075-753-9501 FAX. 075-753-9500

2 Overall Concept

Kyoto UniversityCenter for Innovation in Immunoregulatory Technology and Therapeutics (AK project)

Overall Person-in-charge Hiroshi Matsumoto (President, Kyoto University)

Researcher (Representative) Shuh Narumiya (Professor, Graduate School of Medicine)

■ By 7th Year (FY2013)

1 Identify and examine at least 25 target molecules. Use spec-

imens from patients to examine clinical relevance of the pro-

posed targets for differentiation from existing drugs to create

game-changing drugs. Proceed the targets on which we can

build the drug discovery concept to the Drug Discovery Program

of Astellas Pharma in which optimization of compounds and an-

tibodies are carried.

2 Develop humanized mice, iPS cell applications, bio-imaging

and simulation of the immune system, and the system and tech-

nology for clinical specimen analysis to search bio-marker and

improve the predictability in the pre-clinical stage so as to in-

crease the success rate in clinical trials.

1 Launch more than three drugs onto the market with indica-

tions in diseases such as rheumatoid arthritis, systemic lupus ery-

thematosus and allergy and as immunosuppressant.

2 Based on the AK project model, will establish a drug R&D

center at Kyoto University, which continues to support industry-

academia collaboration and enhance international competitive-

ness of drug industry in Japan.

■ By 10th Year (FY2016)

1 Will complete evaluation of efficacy and safety of candidate

compounds, biologics and new medical technology in pre-clini-

cal test and will create more than three drugs to launch. Phase I

clinical trials on drug candidates ready by this time will be started

either by the company or at the Translational Research Center of

Kyoto University.

2 Will produce more than 20 medical scientists and other tal-

ents specialized in drug discovery as senior researchers and ten-

ured staffs in universities, companies, government agencies, and

other organizations.

The purposes of the AK project are i) devel-

opment of “next-generation immunoregula-

tory medicines” by combining drug discovery

technologies of Astellas Pharma and basic

and clinical research in Kyoto University Grad-

uate School of Medicine and Kyoto University

Hospital, ii) creating a model of industry-

academia collaboration for drug discovery in

the post-genome era, and iii) nurturing sci-

entists and other talents specialized in drug

discovery. Specifically, we have established

the Fusion labolatory in the campus of Kyo-

to University Graduate School of Medicine,

where researchers from Graduate School of

Medicine of Kyoto University work togeth-

er with researchers from Astellas Pharma in

order to carry out interdisciplinary research

and establish an efficient drug discovery R&D

system. Through these efforts, we aim to de-

velop innovative drugs in immunology area

to fulfill unmet medical needs in intractable

diseases such as allergies, autoimmune dis-

eases, chronic inflammatory diseases, chronic

infectious diseases, organ transplantation and

cancer. By such accomplishment, we will con-

tribute to the health and welfare of human

beings, and strengthen the international com-

petitiveness of the pharmaceutical industry in

Japan. Furthermore, we nurture and produce

scientists and other talents specialized in drug

discovery, who possess integral knowledge

and skills in medicine, drug discovery, intel-

lectual property and other related fields, and

who function as the interface between indus-

try and academia to promote drug discovery

in future.

Developping “Next-generation immunoregulatory therapeutics” by combining drug discovery technologies of Astellas Pharma and medical research of Kyoto University

RESEARCH THEME

3 Discovery of new drugs for atopic dermatitis

Keratinocytes in the skin

ep i the l ium funct ion as

a barrier against foreign

substances. In atopic der-

matitis, this keratinocyte

barrier is impaired because

o f down- regu la t ion o f

expression of filaggrin, a

cross-linker of keratin and a source of natural moisture

substances. At this project, we collaborate with De-

partment of Dermatology, Kyoto University Hospital, to

create an innovative drug that is capable of restoring im-

paired skin barrier in atopic dermatitis patients by upreg-

ulaiton of filaggrin expression and therefore differs from

steroids traditionally used in this disease.

Social Value Improve QOL of patients.

Economic Value As an orally active drug, substitute for

steroid ointment and make a new market.

106.8 billion yen/year (Japan, the U.S., Europe); expected

launch in 2027, 11 years after the end of the implemen-

tation project

Results to Date Obtained a tool compound that upreg-

ulates the filaggrin expression in cultured skin cells and

shows improvement of the conditions in a mouse model

of atopic dermatitis. Large-scale compound exploration

on the target molecule of this compound is being imple-

mented.

Kyoto UniversityCenter for Innovation in Immunoregulatory Technology and Therapeutics (AK project)

1 Discovery of new drugs for rheumatoid arthritis (RA)

Rheumatoid arthritis (RA) is a disease of inflammation

of the synovial membrane in the joint, causing swelling,

continuous inflammation, pain, and deformation of af-

fected joints. While introduciton of anti-TNF therapy has

significantly improved its treatment, the effectiveness

and remission rate are still insufficient, and infection

caused by immunosuppression also occurs. At this pro-

ject, we therefore extract information thorugh analysis

of patient samples and create a novel type of drugs that

work directly on synovial membrane to suppress inflam-

mation and prevent joint damage.

Social Value Improvement in QOL of RA patients and

loss of the social labour force due to this disease by

achievement of higher remission rate in RA patients

including those unresponsive to existing drugs (such as

anti-TNF drugs).

Economic Value Reduction in costs for treating RA pa-

tients by decreasing the number of surgeries for synovial

membrane removal and joint replacement for patients

unresponsive to existing drugs as well as avoiding infec-

tions accompanying existing drugs, and by increasing

the proportion of patients with remission and drug-free

maintenace.

268.7 billion yen/year (Japan, the U.S., and Europe);

expected launch in 2026, 10 years after the end of the

project

Results to Date Identified a target molecule by analysis

on synovial membrane tissue of RA patients, the anti-

body against which suppresses thickening of human syn-

oviocytes and shows high effectiveness in animal model

of the disease. Various lines of studies are being carried

out to develop this antibody as a clinical medicine.

2 Discovery of new drugs for systemic lupus erythematosus (SLE)

SLE is triggered by deposition of immunocomplex of cell

components and their auto-antibodies in the tissues such

as kidney, skin and brain, which eventually causes injury

of these tissues by inducing lymphocyte attack. SLE is

frequent in pubescent and post-pubescent females. The

etiology of SLE is not yet known, and symptoms differ

from patient to patient. At this project, we combine

analysis of its pathogenesis by basic immunology, analy-

sis of patient specimens with clinicians for validation and

patient stratification, and analysis of therapeutic efficacy

of antibodies created by Astellas Pharma in animal mod-

els to develop new treatment for this intractable disease.

Social Value Due to its superior therapeutic effect and

excellent safety, the drug can substitute for current drugs

including cyclophospha-

mide and MMF and be

expected to administer

sa fe l y to women o f

fertile capacity, thus ex-

panding the number of

applicable patients.

Economic Value Drastic

reduction in the cost for

SLE patients by reducing

the dose of steroid, which is not possible with existing

drugs, and preventing its adverse effects such as bone

fracture, infection, hypertension, and hyperlipidemia.

105.8 billion yen/year (Japan, the U.S., Europe); expected

launch in 2027, 11 years after the end of the project.

Results to Date Identified a new drug target and mecha-

nism that may cause kidney injury and facilitate autoanti-

body production from the findings of basic immunology

research. An antibody against this molecule improved the

pathology in an SLE animal model. Creation of a human

antibody is in progress.

In-Depth Focus 06

In-Depth Focus 05 Osaka University

Tohoku University

In-Depth Focus 07

The University of Tokyo 東京大学The University of Tokyo

The keyword for emerging industrial technology in this 21st century is photonics. Osaka University’s Photonics Advanced Re-search Center aims to innovate science and industries by combining photonics, nanotechnology and biotechnology.

Together with Shimadzu Corporation, one of the member companies, this project pursued applied research on plas-ma photonics to develop the gas chromatograph Tracera, which features significantly enhanced detection sensitivity and is now marketed throughout the world by Shimadzu Corporation. The system is also capable of handling more samples than those with conventional detection methods.

Commercialization of tip-enhanced Raman scattering nanomicroscope

Productization of a new high sensitive gas chromato-graph system

Photonics Advanced Research Center Photonics (Science and Technology of light)

Kyushu University

Prototype of portable ReMI equipment with magnetic circuit

In-Depth Focus 08

Innovation Center for Medical Redox Navigation

towards the development of drugs and the establishment

of early diagnosis and treatment methods for redox-re-

lated diseases. Thus far, development of redox measuring

technology using the Overhauser effect has been carried

out, and a new type of MRI equipment (ReMI) in which

the magnetic circuit moves precisely has been developed.

This equipment allows the disease mechanism to be un-

derstood and visualized, and this is further expected to

lead to a new kind of medical diagnosis technology and

drug efficacy image analysis in drug development, includ-

ing with regard to anti-oxidation drugs.

Kyushu University Hospital, west wing “Innovation Center for Medical Redox Navigation”

R&D Center of Excellence for Microsystem Integration Research InitiativeDevelopment of integrated micro-biosensor system (through industry-industry-academia collaboration)

Jun 2, 2012 Nikkan Kogyo Shimbun

Manufactured bio-LSI measurement system (the LSI in the newspaper article photo is built-in)

Tohoku UniversityBio-sensing research based on electrochemical reaction using a 2D array LSI

Roles in industry - industry - academia collaboration

Development of device package and measurement system

Japan Aviation Electronics Industry

ToppanLSI design and creation using shared wafer sysytem

In recent years, excessive free radicals have been pro-

duced due to various changes in environmental factors

and unhealthy lifestyle, resulting in a breakdown of the

redox balance. As a result, the possibility that cancer,

lifestyle diseases, heart diseases, and the like may arise

has been pointed out. For example, 60% of the deaths

in Japan are said to be related to lifestyle diseases, and

thus the creation of advanced interdisciplinary medicine

focusing on redox is thought to be a national priority.

In this research center, researchers in medicine, phar-

macological, agriculture,

and engineering gather at

dedicated laboratories (about

2,000 m2) on the 5th and

6th floors of the west wing

within the university hospital

campus to carry out research

with the aim of creating ad-

vanced interdisciplinary med-

ical research areas oriented

The project succeeded in product development of tip-en-hanced Raman scattering microscope that utilizes light intensity enhancement by plasmon resonance at nano-meter scale. The product is now to be sold from a startup company. The technology has been under basic research for 20 years. The manufacturing of sharp nano-structured metal probes is one of the key technologies.

The system is made up of 20x20 current detection arrays, ampli-fication electrodes and LSI on top of which liquid reservoirs (with liquid specimens inside) are constructed. By capturing the chang-es in the current due to the electrochemical reaction that occurs in liquid specimens such as an enzyme in the reservoirs, DNA, bio-molecules, etc., the analysis of the behaviour and identifica-tion of type can be carried out in real time.

Translational Systems Biology and Medicine Initiative

【Participating in national politics】Advisor to the Office of Healthcare Policy un-der the Cabinet Secretariat: Yoichiro Matsumoto (Vice President, The University of Tokyo; Professor, School of Engineering)

Deputy Center Director (for Medical Devices), Phar-maceuticals and Medical Devices Agency (PMDA) : Ichiro Sakuma (Deputy Head of Research Center)

In an ageing society such as Japan where the number of deaths is increas-ing rapidly, the main causes of death are cancer, stroke, and heart diseas-es caused by lifestyle diseases. Treatments are invasive, with significant side effects, and the financial situation is dire due to high medical costs. In addition to systematically and comprehensively identifying cell-specific target proteins in cancer and lifestyle focal lesions based on translational systems biology and medicine, this center also aims to commercialize in-novative drugs and medical devices at a low cost and with few side effects by combining both diagnosis and treatment and by fusing less invasive, high-precision medical devices with imaging using an artificial protein probe together with collaborating organizations. The head of the research center, Professor Takashi Kadowaki, is a preeminent scholar in diabetes research who has achieved significant results and made numerous contri-butions over many years in the medical world. In 2010, 2011, and 2013, he was awarded the Purple Ribbon Medal, the Takeda Medical Science Prize, and the Japan Academy Award, respectively.

In the development and analysis of bio-marker measurement technology using clinical specimens, the development of the LCMS-8050 mass spectrometer, which provides sensitivity that is 10 times higher than that of existing models, has been successfully completed ahead of schedule, and sales were launched by Shimadzu Corporation on Aug 22, 2013. Furthermore, using this device, the possibility of BNP (5-32) and BNP (3-32) becoming new bio-markers for coronary restenosis was also demonstrated (Clinical Chemistry published May 13, 2013, as doi: 10.1373/clinchem.2013.203406).

Recent well-noted achievements

rs for A

s Prog

Yokohama City UniversityEstablishment of Research Center for Clinical Proteomics of Post-Translational Modifications

Development of analytical technology by combining technologies in the medical, pharmaceutical, scientific, and engineering fields

ORGANIZATION

Name Yokohama City University

U R L http: //www.yokohama-cu.ac.jp/shincho/

Address 22-2, Seto, Kanazawa-ku, Yokohama-shi, Kanagawa Prefecture TEL. 045-787-2441 FAX. 045-787-2025Overall Person-in-charge Katsuko Tanaka (Chairperson, Yokohama City University)

Researcher (Representative) Hisashi Hirano

Collaborating Organizations : Medical ProteoScope Co.,

Ltd., Lion Corporation, FUJIFILM Corporation, Eisai Co., Ltd.,

FANCL Corporation, TOSOH Corporation, Sekisui Medical Co.,

Ltd, Toyama Chemical Co., Ltd., CellFree Sciences Co., Ltd.

Complete the development of a foundation to create innovative

analytical technologies that are necessary for the establishment

of the research center. Identify more than a thousand abnormal

PTM proteins related to diseases using these technologies. Dis-

cover the physiological functions and relationships with diseases

for a hundred or more of these proteins. Clarify the spatial struc-

ture of 10 or more abnormal PTM proteins to create a founda-

tion for drug design. Enable the development of drug targets

and biomarkers within a short period of time.

Build a mutually complementary and innovative framework for

the university/the university hospital and companies to return

research achievements to society for a new social order while

fulfilling the traditional social roles of the university/the university

hospital in manpower development and in promoting basic and

applied research. Send young researchers nurtured at this center

to other research institutions to raise the research standard in

Japan and enhance international competitiveness in the field of

research on diseases that are caused by abnormal post-transla-

tional modifications in proteins.

Aim to commercialize mass spectrometers that can be used in

clinical examination and effectively detect abnormal post-trans-

lational modifications. Attempt drug design based on the results

of analysis of the spatial structure of abnormal PTM proteins.

Clarify the correlation between PTM level and patient condition,

applications towards the early discovery of diseases and pharma-

cokinetic studies, and possibility of predicting the treatment ef-

fects of developmental drugs. The creation of a discovery profile

for PTM proteins will open up a path to innovative personalized

medicine.

2 Overall Concept

The proteomics, medical, and engineering

research teams of Yokohama City University

and companies that possess advanced ana-

lytical technologies aim to collaborate with

one another in creating a medical research

center for clinical proteomics of post-transla-

tional modifications. The center will develop

high-throughput technologies that can detect

post-translational modifications in proteins

at a high sensitivity, and search for proteins

that will become diagnosis markers and drug

targets by comprehensive analysis on a large

scale of relationship between diseases and

post-translationally modified (PTM) proteins

at the molecular level. In addition to evalu-

ating the proteins discovered using genome

analysis, in vivo imaging techniques, and the

like, development of innovative assay meth-

ods for diagnostic markers will also be carried

out. Furthermore, the spatial structure of

the drug targets will be analyzed and drug

design will be carried out with the aim of de-

veloping new drugs. A new research center

will be formed through the construction of

a new Advanced Medical Research Center

building together with the establishment of

research laboratories for bioinformatics and

in vivo synthesis of proteins, and also through

supporting junior research teams, conducting

symposiums, and the like.

New building of the Advanced Medical Research Center

(construction completed in Dec 2012)

（）Professor, Director of the Advanced Medical Research Center of Yokohama City University

RESEARCH THEME

Yokohama City UniversityEstablishment of Research Center for Clinical Proteomics of Post-Translational Modifications

1 Development of basic technologies and biomarkers

Develop advanced technologies for mainly mass spec-

trometry that are capable of analyzing the relationship

between diseases and abnormal PTM proteins. With this

as a foundation, carry out a comprehensive and large-

scale analysis of proteins whose expression fluctuates in

accordance with the disease using specimens from pa-

tients suffering from cancer, mental disorders, immuno-

logical diseases, and the like so as to advance the search

for biomarkers and drug target proteins.

Social Value The possibility of this leading to the devel-

opment of diagnostic and treatment methods for high

profile diseases such as cancer, lifestyle diseases, and the

like is high.

Economic Value Commercialization of analysis is possible

through the development of analytical technologies and

sales of analytical equipments.

2.34 billion yen/10 years after end of implementation

period

Results to Date Basic technologies for the research

center were developed in the first half of the project.

The technology to detect and identify 3,000 plasma

proteins, the technology to detect and identify more

than 2,000 phosphorylated proteins and 4,000–6,000

phosphorylated sites using a mass spectrometer with

an improved scanning method to analyze quantitatively

phosphorylated peptides have been established. The

technology to monitor phosphorylated proteins using

affinity electrophoresis and a new post-translational

modified peptide dissociation method (electron capture

dissociation method and hydrogen atom transfer dissoci-

ation method) have been developed. Large-scale analysis

of post-translationally modifications such as GPI anchor

addition, acetylation, glycosylation, myristoylation, meth-

ylation, and ubiquitylation has also been made possible.

Research to detect and identify abnormal PTM proteins

using these technologies and to investigate their rela-

tionship with functions and disease is on-going.

3 Development of functional foods and cosmetics

Research to investigate the action mechanism of func-

tional foods like lactoferrin that have an effect of lower-

ing visceral fat is being carried out using proteomic tech-

nique. Research to discover new biomarkers that target

proteins related to the skin and health condition of the

whole body and research that aims to apply them to skin

diagnosis technologies and high-precision counseling are

also being carried out.

Social Value This will lead to the creation of functional

products useful for health promotion.

Economic Value Functional products with high economic

value can be sold through patent acquisition.

2 billion yen/10 years after end of implementation period

Results to Date The action mechanism of functional

foods like lactoferrin that have an effect of lowering vis-

ceral fat has been analyzed using proteomic techniques.

The role that lactoferrin plays in the expression control of

important proteins involved in lipolysis and the stimula-

tion of the cAMP signaling pathway, which has been the

general lipolysis route to date have also become clearer.

Research to analyze the functional peptides that appear

in blood and reflect the health condition of the entire

body including skin after collagen intake is also on-go-

Development of diagnostic and treatment drugs for cancer, mental disorders, and immunolog-ical diseases

In addition to analyzing the functions of the proteins and

the correlation between disease and abnormal PTM pro-

teins identified in the patient specimens, model cells, and

the like, carry out research to evaluate and verify their

usefulness as biomarkers and drug target molecules, and

on the discovery of drug compounds that target abnor-

mal post-translational modifications in proteins related to

the disease.

Social Value The possibility of this leading to the devel-

opment of diagnostic and treatment methods for high

profile diseases such as cancer, neuropsychiatric disor-

ders, and the like is high.

Economic Value The possibility of commercializing drug

targets and biomarkers using 1/10–1/50 of the time and

efforts previously required is high. New drugs can be

developed and economic value can be added through

patent acquisition.

303.6 billion yen/10 years after end of implementation

period

Collaborating Organizations : Medical ProteoScope Co., Ltd., TOSOH Corporation, Sekisui Medical Co., Ltd.

Collaborating Organizations : Lion Corporation, FANCL Corporation

Collaborating Organizations : FUJIFILM Corporation, Eisai Co., Ltd., Toyama Chemical Co., Ltd., LTD, CellFree Sciences Co., Ltd.

Results to Date Abnormal PTM proteins related to can-

cer, neuropsychiatric disorders, and the like have been

detected and identified using basic technologies that

have been developed. The relationship between disease

and detected proteins has also been verified, and po-

tential biomarker proteins that can be used in diagnosis

have been discovered. Furthermore, many proteins that

have a high possibility of becoming drug targets have

been identified. Meanwhile, significant results have been

obtained in the screening of drug compounds that target

proteins related to prostate cancer, HIV, intractable men-

tal disorder, rheumatoid arthritis, Huntington’s chorea,

medulloblastoma, and the like.

rs for A

s Prog

National Institute of Advanced Industrial Science and Technology (AIST)Vertically Integrated Center for Technologies of Optical Routing toward Ideal Energy Savings (VICTORIES)

ORGANIZATION

Name National Institute of Advanced Industrial Science and Technology (AIST)

U R L http: //www.aist-victories.org/

Address Central 2, 1-1-1, Umezono, Tsukuba-shi, Ibaraki Prefecture TEL. 029-861-5254 FAX. 029-861-5255

R&D based on the vertical integration of technologies ranging from devices to system devices to network resource management

Overall Person-in-charge Ryoji Chubachi

Researcher (Representative) Shu Namiki (Director, Network Photonics Research Center)

Collaborating Organizations : Nippon Telegraph and Tele-

phone Corporation, Fujitsu Laboratories Ltd., Furukawa Electric

Co., Ltd., Trimatiz Ltd., NEC Corporation, Fujitsu Ltd, Fujikura

Ltd., Alnair Labs Corporation, Sumitomo Electric Industries,

Ltd., Kitanihon Electric Cable Co., Ltd.

1 Complete the development of basic technologies for dynamic

optical path networks. Create transmission path optimization

equipment and time division multiplexing switches.

2 Carry out an actual operational demonstration of an optical

path network in the Tsukuba region using developmental tech-

nologies to verify low power consumption and large transmission

capacity.

1 Growing in the use of dynamic optical path networks in actual

networks.

2 Promote research and development in communication tech-

nologies that can meet the requirements of society as an innova-

tion center based on the technologies cultivated in the research

center.

1 Upgrade the developmental technologies and create products

such as dynamic ROADM, wavelength selection switches, and

small-scale matrix switches.

2 Verify the ultra-low power consumption and convenience of

a dynamic optical path network in applications such as video

transmission through a field verification test over a wide area.

2 Overall Concept

In recent years, the volume of information

flowing through networks has increased rap-

idly, and thus the power consumption of the

entire network, including routers, has also

been increasing. To realize an information

society that can continue to grow on a sus-

tainable basis, it is crucial to drastically reduce

the energy consumed by networks. This re-

search center aims to resolve this problem by

developing a dynamic optical path network

technology whose energy efficiency is on 3–4

orders of magnitude higher than traditional

networks.

This is a new type of network that dynami-

cally provides an optical path to connect ter-

minal points between users through optical

switches. In order to realize this, the National

Institute of Advanced Industrial Science and

Technology has formed an R&D center to-

gether with ten collaborating organizations

to vertically integrate technologies such as

optical switches, system devices, network ar-

chitecture, and control systems. Development

of international researchers who are capable

of envisioning a wide scope on technologies

in areas ranging from devices to architecture

will also be carried out in the center.

（）President, National Institute of Advanced Industrial Science and Technology

RESEARCH THEME

National Institute of Advanced Industrial Science and Technology (AIST)Vertically Integrated Center for Technologies of Optical Routing toward Ideal Energy Savings (VICTORIES)

1 Development of Dynamic Optical Path Network

Study the architecture of a dynamic optical path network

that operates with an improvement in energy efficiency

over that of current networks on an order of 3–4 digits,

integrate the component technologies, and carry out val-

idation of the network.

Social Value Realize an information society that is able

to grow sustainably and in which large amounts of data,

such as for high definition images, can be used exten-

sively without being constrained by energy consumption

so as to change the economy, society, and living environ-

Economic Value A network-related market to achieve an

ultra-large capacity at ultra-low energy consumption will

be formed. New applications markets will emerge, with

a great variety such as telepresence, ultra-high-definition

video-on-demand, etc..

Approximately 1.2 trillion yen/10 years after end of im-

plementation period (in Japan)

Results to Date A study on the basic functions and con-

figuration of the nodes required for a dynamic optical

path network has been completed, and the construction

of a test bed has been started within the campus of the

AIST. The design based on a regular grid topology with 3

x 3 core nodes is ongoing, and a large-scale demonstra-

tion test to transmit an ultra high-definition 8K resolu-

tion video in real time will be carried out in Oct 2014.

Collaborating Organizations : Nippon Telegraph and Telephone Corporation, Fujitsu Laboratories Ltd., Furukawa Electric Co., Ltd., Trimatiz Ltd.,

NEC Corporation, Fujitsu Ltd, Fujikura Ltd., Alnair Labs Corporation, Sumitomo Electric Industries, Ltd., Kitanihon Electric Cable Co., Ltd.

3 Optical path processor

Develop an optical matrix switch based on silicon pho-

tonics that switches the optical path dynamically at the

fiber level and wavelength selection switches that switch

the optical path at the wavelength level.

Social Value As targeted in the overall concept, an in-

formation society that can grow sustainably will be real-

ized through the development of new switches.

Economic Value A new network-related market for opti-

cal devices to achieve ultra-large capacities at ultra-low

energy consumption will be formed.

100 billion yen/10 years after end of implementation pe-

riod (in Japan)

Results to Date The world’s smallest PILOSS 8 x 8 optical

matrix switch has been produced successfully and its ba-

sic operations and performance have been verified.

Collaborating Organizations : Fujitsu Laboratories Ltd., NEC Corporation, Furukawa Electric Co., Ltd., Kitanihon Electric Cable Co., Ltd.

Collaborating Organizations : Nippon Telegraph and Telephone Corporation, NEC Corporation, Fujitsu Ltd, Sumitomo Electric Industries, Ltd.,

Furukawa Electric Co., Ltd., Trimatiz Ltd., Fujikura Ltd., Alnair Labs Corporation, Fujitsu Laboratories Ltd.

Schematic illustration of test bed

2 Network devices

Development of dynamic optical node devices capable of

supporting data in diverse capacities, and technologies

for the integrated management of networks and storage

as well as for the optimization of network transmission

paths will be carried out.

Social Value As targeted in the overall concept, an in-

formation society that can grow sustainably will be real-

ized through the development of new network devices.

Economic Value A network-related market to achieve ul-

tra-large capacities at ultra-low energy consumption will

be formed.

Approximately 1.1 trillion yen/10 years after end of im-

plementation period (in Japan)

Results to Date The basic operation of a multi-granular

-hierarchical node system has been verified using dy-

namic modules such as optical switches and wavelength

selective switches. The intermediate control interface

for efficiently controlling the node system has also been

defined, and been applying to control many different de-

vices modules.

Dynamic display of multi-granular, multi-hierarchical node (AIST Open Lab 2013)

The world’s smallest PILOSS 8×8 optical matrix switch

rs for A

s Prog

Kobe UniversityInnovative Bio Production Kobe (iBioK)

ORGANIZATION

Name Kobe University

Address 1-1, Rokkodai-cho, Nada-ku, Kobe-shi, Hyogo Prefecture TEL. 078-803-5340 FAX. 078-803-5349

Interdisciplinary research that combines agriculture and engineering with the aim of material production (bio-production) that makes use of bio-resources as effectively as possible

Overall Person-in-charge Hideki Fukuda (President, Kobe University)

Researcher (Representative) Akihiko Kondo (Professor, Graduate School of Engineering)

Collaborating Organizations : ASAHI KASEI CHEMICALS

CORPORATION, EZAKI GLICO CO., LTD., Kaneka Corpora-

tion, Gekkeikan Sake Company, Ltd., COSMO OIL CO., LTD.,

DAICEL CORPORATION, TEIJIN LIMITED, Nagase & Co., Ltd.,

NITTO DENKO CORPORATION, NIPPON SHOKUBAI CO., LTD.,

NIPPON PAPER INDUSTRIES CO., LTD., Bio-energy Corporation,

Fujicco Co., Ltd., Mitsui Chemicals, INC.

1 Collaborate with 5 or more research institutions overseas and

develop at least one of them to the national project level.

2 Partner with 14 collaborating organizations and aim to estab-

lish scale-up technologies for producing materials from biomass

for 6 or more of the target materials.

3 Aim to establish a “Graduate School of Bio-Refinery” that

integrates the two disciplines in the Graduate School of Agricul-

tural Science and Graduate School of Engineering based on the

achievements up to the 7th year.

At the end of the implementation period for the research center,

a “Kobe University Bio-Refinery Organization” will be established

as an external body to manage the royalties received from com-

panies for the use of intellectual property that has been created

by this center as operational funds. Collaborative research will

be further widened to grow the center sustainably. “Joint Tech-

nology Groups” will also be established with multiple corporate

organizations for commercialization purposes.

1 Implement material production at the bench scale level at all

14 companies participating in the conceptual plan for the cre-

ation of the research center.

2 Aim to collaborate with 10 or more research institutions in

Europe, the U.S., and Asia, and establish the international stand-

ing of this research center.

3 Turn out personnel with recognized research skills and corpo-

rate adaptability in the business world and establish the social

recognition of this research center.

2 Overall Concept

This center aims to create a sustainable,

low-carbon society through green innovations

using advanced biotechnologies to com-

mercialize the bio-production of important

bio-products such as next-generation fuel,

synthesized raw materials, bio-plastics, bio-fi-

bers, and bio-fine chemicals from renewable

biomass resources. “Research Engines” in 6

core research areas that boast the originality

and eminence of Kobe University will be es-

tablished and promoted through industry-in-

dustry-academia partnerships. In addition to

creating process innovations and commer-

cializing bio-products through an integrated

bio-process, product innovation to create

new materials will also be carried out. Person-

nel who are capable of making assessments

based on a comprehensive understanding of

bio-production while taking global circum-

stances into account will also be nurtured.

Furthermore, research interaction for the

purpose of promoting industry-industry-aca-

demia collaboration and the “Bio-Restaurant”

intellectual property system will be strongly

promoted.

U R L http: //www.org.kobe-u.ac.jp/bioproduction/

RESEARCH THEME

Kobe UniversityInnovative Bio Production Kobe (iBioK)

4 Development of Basic Technologies

Companies aim to commercialize products required to

build integrated bio-processes for biomass production,

pre-processing, bio-processing, film processing, and the

like, among core basic technologies developed by Kobe

University.

Results to Date Development of these basic technolo-

gies is ongoing, and application of these technologies

towards bio-production in collaboration with other com-

panies has reached the doorstep of commercialization.

The establishment of bio-production technology to produce various bio-products from renewable biomass involves the

development of green innovations for large-scale conversion of products made from petroleum in chemical factories

to bio-products. With Kobe University, which leads Japan in bio-refinery research, playing a leading role, this research

center is an initiative to create Japan’s largest bio-refinery for the commercialization of key bio-products through indus-

try-academia collaboration. By creating and closely promoting six key research engines” that integrate the unique lead-

ing technologies of Kobe University through collaboration between the Agriculture and Engineering faculties, Bio-pro-

duction will be institutionalized as an advanced interdisciplinary research domain.

2 Bio-plastics, Bio-fibers

Aim for the bio-production of organic acids, diamines,

amino acids, and aromatic compounds that have been

selected as key chemicals. Furthermore, develop environ-

mentally friendly technology to synthesize bio-plastics

and bio-fibers.

Results to Date Nine types of compounds have been

produced successfully to date and scale-up studies are in

progress. Productivity for certain target compounds has

been improved by 15 times or more. Appropriate targets

for market launch have been set for each compound,

and steady progress in research is being made.

Collaborating Organizations : DAICEL CORPORATION, TEIJIN LIMITED, Bio-energy Corporation, Mitsui Chemicals, INC.

1 Next Generation Fuel, Synthesized Raw Materials

Aim for the bio-production of alcohols and diols that

have been selected as key chemicals.

Results to Date Four types of compounds have been

produced successfully to date, and scale-up studies are in

progress. Productivity for certain target compounds has

been improved by 40 times or more. Moreover, bench

production tests at a 90-L scale are also ongoing, with

steady progress being made towards commercialization.

Collaborating Organizations : ASAHI KASEI CHEMICALS CORPORATION, NIPPON SHOKUBAI CO., LTD.

3 Bio-fine Chemicals

Aim for the bio-production of functional sugars, useful

inositols, function peptides, functional phospholipids,

Results to Date Ten or more types of compounds have

been produced successfully thus far, and functional eval-

uations and scale-up studies are in-progress. Technology

to scale up production of certain target compounds to a

scale of 900 L has been established. Appropriate targets

for market launch have been set for each compound,

and steady progress in research is being made.

Collaborating Organizations : EZAKI GLICO CO., LTD., Kaneka Corporation, Gekkeikan Sake Company, Ltd., COSMO OIL CO., LTD., Nagase

& Co., Ltd., Fujicco Co., Ltd.

Social Value This will have a great impact on the foun-

dation for the sustainable development of the country in

future, such as through release from dependence on oil,

energy conversion, significant reduction in CO2 emissions,

resource and energy security, and stimulation of agricul-

ture, forestry, and fishery.

Economic Value Based on global trends in the market

for bio-products, large-scale expansion of bio-fuels and

bio-processed products is expected sometime from 2020

to 2030. An enormous market can be created by focus-

ing on research and development in preparation for this.

Collaborating Organizations : ASAHI KASEI CHEMICALS CORPORATION, Gekkeikan Sake Company, Ltd., Nagase & Co., Ltd., NITTO DENKO CORPORATION, NIPPON PAPER INDUSTRIES CO., LTD., Bio-energy Corporation

At the “Innovative Bio Production Kobe (iBioK)” center, im-portant bio-products are rolled out in the market to realize green innovations and divert raw materials used from petro-leum to biomass.

Mass-produced next-generation fuel, synthesized raw mate-rials, bio-plastics, and bio-fibers, as well as high value-added bio-fine chemicals are three of the targeted product groups to be produced from biomass. Basic technologies that sup-port bio-production will also be commercialized so that they can be applied to even more chemicals.

Kobe University is the leading bio-refinery research authority in Japan. The agriculture and engineering faculties of the university will collaborate with 14 leading chemical compa-nies in Japan to build an international research center for accelerating the development of green innovations. Besides establishing the basic technologies for bio-production, the center will aim to commercialize important bio-products and become the core center for the formation of bio-combinates.

So far, the center has succeeded in raising the production volume of higher-order alcohols and organic acids by several times to several tens of times, and steady progress has been made towards commercialization through scale-up opera-tions. New fine chemicals and building blocks that will serve as new materials continue to be discovered in succession,

leading to the creation of new industries and new markets.

The 14 collaborating organizations are not simply a col-lection of companies. With Kobe University at the center, they collaborate closely with one another while shouldering different roles to form bio-combinates. This research center is an initiative to create Japan’s largest bio-refinery through industry-academia collaboration.

“Innovative Bio Production Kobe (iBioK)”

In-Depth Focus 12 Kobe University

In-Depth Focus 11

Vertically Integrated Center for Technologies of Optical Routing toward Ideal Energy Savings (VICTORIES)

The world’s smallest 8 × 8 optical matrix switch successfully fabricated

(a) Optical microscope image of 8 × 8 optical matrix switch. (b) Mounted switch chip on ceramic interposer.

An optical matrix switch switches optical paths at the

fiber level, which is one of the most important compo-

nents comprising the dynamic optical path network. At

the National Institute of Advanced Industrial Science and

Technology, the world’s smallest 8 × 8 optical matrix

switch (shown in the figure below) has been fabricated

successfully using Si photonics technology. The size of the

fabricated optical matrix switch is 2.4×3.5 mm2, which

is 1/550 as small as that of a traditional optical matrix

switch based on silica. This achievement has been accept-

ed as a post deadline paper in the European Conference

and Exhibition on Optical Communication, which is one

of the world’s most authoritative international confer-

ences for optical communications, and acknowledged as

the latest key achievement in this area (K. Suzuki, et al., ECOC 2013, PD2.D.2.).

In-Depth Focus 10 Yokohama City University

The synaptic delivery of AMPA receptors is an attractive

event as a molecular basis of neural plasticity. However,

clinical application of AMPA receptor mediated synaptic

plasticity is still very limited. Through various post-transla-

tional modifications to control the synaptic trafficking of

AMPA receptors, Professor Takuya Takahashi et al. have

shown the relationship between the synaptic delivery of

AMPA receptors and mental disorders and carried out

research for the clinical applications such as drug discov-

ery and diagnosis. In order to examine the mechanisms

of a variety of mental disorders that are caused by child

abuse (eg. neglect), Professor Takahashi et al. examined

the effect of early social isolation on the synaptic delivery

of AMPA receptors. They found that early social isolation

attenuates experience-driven synaptic AMPA receptor

delivery through the abnormal post-translational modifi-

cation detected by the mass

spectrometer in this research

center. Furthermore, they found

abnormal c ircuit formation

and behaviours in isolated animals (Miyazaki et al. J. Clin.

Invest. 2012). Meanwhile, a rich environment facilitates

synaptic AMPA receptor delivery via the activation of sero-

tonergic system through the changes in phosphorylation

of AMPA receptors (Jitsuki et al. Neuron 2011). Further-

more, synaptic AMPA receptor delivery is required for the

formation of fear memory (Mitsushima et al. PNAS 2011,

Mitsushima et al. 2013 Nature Communications). Based

on these findings, leading compounds that control neural

plasticity were identified in cooperation with the organiza-

tions involved in this research center. This potentially leads

to clinical applications.

Pursuing the link between brain plasticity and neuropsychiatric disorders

Aim for the creation of a center that can conduct comprehensive research on the relationship between diseases and post-translational modifications in proteins using advanced proteomics analytical technologies.

Professor Takahashi

Kyoto University National Institute of Advanced Industrial Science and Technology (AIST)In-Depth Focus 09

Center for Innovation in Immunoregulatory Technology and Therapeutics (AK Project)

Under the slogan "Best Drugs on Best Science," Kyoto Univer-

sity and Astellas Pharma Inc. are collaborating to create new

innovative drugs in the immunology area including allergy such

as atopic dermatitis and pollinosis, autoimmune disorders such

as rheumatoid arthritis and SLE, cancer immunotherapy, and

immunosuppression in regenerative medicine.

In Japan, Kobe University is the only large research center for industry-academia collaboration

This center is the first in the world to promote everything from the development of an integrated bio-process to the formation of bio-combinates through industry-industry-academia collaboration

Creation of Innovation Centers for Advanced Interdisciplinary

Documents

PowerPoint Presentation•Pathway driven •Interdisciplinary team model •The Centers for Medicare & Medicaid Services (CMS) defines observation care as a specific, defined set of

CENTERS OF EXCELLENCE & RESEARCH …...3 The Centers of Excellence program and its private sector partners have created or contributed to the creation of over 60 jobs with an estimated

Da Vinci Center for Innovation Project Virginia ... · preneurship, and a venture creation mindset through interdisciplinary collaboration. ... spiritual and practical. Before the

Strengthening Interdisciplinary Partnerships through ... · Family Health Centers of San Diego . Jennifer Fuller-Christie, FNP . Family Health Centers of San Diego. Mark Manning,

Aerospace Engineering MSAE Graduate Program Handbook · several innovative curriculum and interdisciplinary research facilities and research centers at UCF, including the Siemens

Recommendations for Evaluating Large, Interdisciplinary Research … · 2013-07-01 · Evaluating Large, Interdisciplinary Research Initiatives/Centers Data Acquisition Acquire all

UEDA Summit 2012: Technology Acceleration, Job Creation & University Engagement: Partnering with MEP Centers for Mutual Benefit (Troppe, Folk & Jennings)

MEDICAL PHYSICS University of Novi Sad Association of Centers for Interdisciplinary and Multidisciplinary Studies and Developmental Research - ACIMSI

Interdisciplinary Chronic Pain Management - DMARehabilityevents.dmarehability.com/files/Interdisciplinary... · Interdisciplinary Pain Management •Comprehensive, co-ordinated team

SSA/AUCD: A National Collaboration. What is AUCD? National network interdisciplinary centers at major universities Developmental, intellectual & other

CAREER Options UNDERGRADUATE PROGRAM in PUBLIC HEALTH · Options . College of Public Health and Human Sciences. Our interdisciplinary approach, research centers and focus on both

4 - Optimizing Data Centers for IoT Revolution - Optimizing Data Centers...requires moving on the spot analytics closer to data creation. rIn future, most of the sensor data generated

PROGRAMME STANDARDS: INFORMATION SCIENCE · Information Science is an interdisciplinary field, studying the creation, acquisition, analysis, organisation, storage, retrieval and dissemination

EPICS FALL 2019 SYLLABUS - Purdue University · Project work centers around the engineering, technology, and computing needs of a community partner, but interdisciplinary team interaction

Faculty as Agents of Change – Group 2 Professional development workshops centers for teaching and learning PFF and GTA programs Creating curricula interdisciplinary

Transportable Biodiversity Centers Creation in Zheltokamenka Quarry, Ukraine

· PDF fileguia de ruas unicamp campus map teaching and research interdisciplinary centers ensino e pesquisa centros e núcleos Hospital de Clínicas University Clinical Hospital

Centers of Research Excellence in Science and Technology ... · broaden perspectives, ... interdisciplinary field of data science through novel approaches in computer science, statistics,

Program for the Development of Interdisciplinary … › fileadmin › Downloads › PDFs › ...2019/08/29 · Development of Interdisciplinary Oncology Centers of Excellence in

Archives, morphological analysis, & XML encoding: … · Archives, morphological analysis, & XML encoding: interdisciplinary methods in the creation of a digital text explorer for